ClickCease
+1-915-850-0900 spinedoctors@gmail.com
Select Page

Migraine

Back Clinic Chiropractic and Physical Therapy Migraine Team. Migraine is a genetic neurological disease, characterized by episodes called Migraine attacks. They are quite different from regular headaches which are non-migrainous. About 100 million people suffer from headaches in the U.S. And 37 million of these people suffer migraines. The World Health Organization estimates that 18 percent of women and 7 percent of men in the U.S. suffer from these headaches. Migraines are called primary headaches because the pain is not caused by a disorder or disease i.e. a brain tumor or head injury.

Some cause pain only on the right side or left side of the head. While others result in pain everywhere. Migraine sufferers can have moderate or severe pain but usually can’t participate in regular activities because of the pain. When a migraine strikes, a quiet dark room may help with the symptoms. They can last for four hours or can last for days. The range of time someone is affected by an attack is actually longer than the headache itself. This is because there is a pre-monitory or build-up, and then a post-drome that can last for one to two days.


Migraine Headache Treatment: Atlas Vertebrae Realignment

Migraine Headache Treatment: Atlas Vertebrae Realignment

Several types of headaches can affect the average individual and each may result due to a variety of injuries and/or conditions, however, migraine headaches can often have a much more complex reason behind them. Many healthcare professionals and numerous evidence-based research studies have concluded that a subluxation in the neck, or a misalignment of the vertebrae in the cervical spine, is the most common reason for migraine headaches. Migraine is characterized by severe head pain typically�affecting one side of the head, accompanied by nausea and disturbed vision. Migraine headaches can be debilitating. The information below describes a case study regarding the effect of atlas vertebrae realignment on patients with migraine.

 

Effect of Atlas Vertebrae Realignment in Subjects with Migraine: An Observational Pilot Study

 

Abstract

 

Introduction. In a migraine case study, headache symptoms significantly decreased with an accompanying increase in intracranial compliance index following atlas vertebrae realignment. This observational pilot study followed eleven neurologist diagnosed migraine subjects to determine if the case findings were repeatable at baseline, week four, and week eight, following a National Upper Cervical Chiropractic Association intervention. Secondary outcomes consisted of migraine-specific quality of life measures. Methods. After examination by a neurologist, volunteers signed consent forms and completed baseline migraine-specific outcomes. Presence of atlas misalignment allowed study inclusion, permitting baseline MRI data collection. Chiropractic care continued for eight weeks. Postintervention reimaging occurred at week four and week eight concomitant with migraine-specific outcomes measurement. Results. Five of eleven subjects exhibited an increase in the primary outcome, intracranial compliance; however, mean overall change showed no statistical significance. End of study mean changes in migraine-specific outcome assessments, the secondary outcome, revealed clinically significant improvement in symptoms with a decrease in headache days. Discussion. The lack of robust increase in compliance may be understood by the logarithmic and dynamic nature of intracranial hemodynamic and hydrodynamic flow, allowing individual components comprising compliance to change while overall it did not. Study results suggest that the atlas realignment intervention may be associated with a reduction in migraine frequency and marked improvement in quality of life yielding significant reduction in headache-related disability as observed in this cohort. Future study with controls is necessary, however, to confirm these findings. Clinicaltrials.gov registration number is NCT01980927.

 

Introduction

 

It has been proposed that a misaligned atlas vertebra creates spinal cord distortion disrupting neural traffic of brain stem nuclei in the medulla oblongata encumbering normal physiology [1�4].

 

The objective of the National Upper Cervical Chiropractic Association (NUCCA) developed atlas correction procedure is restoration of misaligned spinal structures to the vertical axis or gravity line. Described as the �restoration principle,� realignment aims to reestablish a patient’s normal biomechanical relationship of the upper cervical spine to the vertical axis (gravity line). Restoration is characterized as being architecturally balanced, being capable of unrestricted range of motion, and allowing a significant decrease in gravitational stress [3]. The correction theoretically removes the cord distortion, created by an atlas misalignment or atlas subluxation complex (ASC), as specifically defined by NUCCA. Neurologic function is restored, specifically thought to be in the brain stem autonomic nuclei, which affect the cranial vascular system that includes Cerebrospinal Fluid (CSF) [3, 4].

 

The intracranial compliance index (ICCI) appears to be a more sensitive assessment of changes made in craniospinal biomechanical properties in symptomatic patients than the local hydrodynamic parameters of CSF flow velocities and cord displacement measurements [5]. Based on that information, previously observed relationships of increased intracranial compliance to marked reduction in migraine symptoms following atlas realignment provided incentive for using the ICCI as the study objective primary outcome.

 

ICCI affects the ability of the Central Nervous System (CNS) to accommodate physiologic volume fluctuations that occur, thereby avoiding ischemia of underlying neurologic structures [5, 6]. A state of high intracranial compliance enables any volume increase to occur in the intrathecal CNS space without causing an intracranial pressure increase that occurs primarily with arterial inflow during systole [5, 6]. Outflow occurs in the supine position via the internal jugular veins or when upright, via paraspinal or secondary venous drainage. This extensive venous plexus is valveless and anastomotic, allowing blood to flow in a retrograde direction, into the CNS through postural changes [7, 8]. Venous drainage plays an important role in regulating the intracranial fluid system [9]. Compliance appears to be functional and dependent on the free egress of blood via these extracranial venous drainage pathways [10].

 

Head and neck injury could create abnormal function of the spinal venous plexus that may impair spinal venous drainage, possibly because of autonomic dysfunction secondary to spinal cord ischemia [11]. This decreases accommodation of volume fluctuations within the cranium creating a state of decreased intracranial compliance.

 

Damadian and Chu describe return of a normal CSF outflow measured at mid-C-2, exhibiting a 28.6% reduction of the measured CSF pressure gradient in the patient where the atlas had been optimally realigned [12]. The patient reported freedom from symptoms (vertigo and vomiting when recumbent) consistent with the atlas remaining in alignment.

 

A hypertension study using the NUCCA intervention suggests a possible mechanism underlying the blood pressure decrease could be resultant from changes in cerebral circulation in relation to atlas vertebrae position [13]. Kumada et al. investigated a trigeminal-vascular mechanism in brain stem blood pressure control [14, 15]. Goadsby et al. have presented compelling evidence that migraine originates via a trigeminal-vascular system mediated through the brain stem and upper cervical spine [16�19]. Empirical observation reveals significant reduction of migraine patients’ headache disability after application of the atlas correction. Using migraine-diagnosed subjects seemed ideal for investigating proposed cerebral circulation changes following atlas realignment as originally theorized in the hypertension study conclusions and seemingly supported by a possible brain stem trigeminal-vascular connection. This would further advance a developing working pathophysiologic hypothesis of atlas misalignment.

 

Results from an initial case study demonstrated substantial increase in ICCI with decrease in migraine headache symptoms following the NUCCA atlas correction. A 62-year-old male with neurologist diagnosed chronic migraine volunteered for a before-after intervention case study. Using Phase Contrast-MRI (PC-MRI), changes in cerebral hemodynamic and hydrodynamic flow parameters were measured at baseline, 72 hours, and then four weeks after the atlas intervention. The same atlas correction procedure used in the hypertension study was followed [13]. 72 hours after study revealed a noteworthy change in the intracranial compliance index (ICCI), from 9.4 to 11.5, to 17.5 by week four, after intervention. Observed changes in venous outflow pulsatility and predominant secondary venous drainage in the supine position warranted additional investigation further inspiring a study of migraine subjects in this case series.

 

The possible effects of the atlas misalignment or ASC on venous drainage are unknown. Careful examination of intracranial compliance in relation to effects of an atlas misalignment intervention may provide insight into how the correction might influence migraine headache.

 

Using PC-MRI, this current study’s primary objective, and primary outcome, measured ICCI change from baseline to four and eight weeks following a NUCCA intervention in a cohort of neurologist selected migraine subjects. As observed in the case study, the hypothesis supposed that a subject’s ICCI would increase following the NUCCA intervention with a corresponding decrease in migraine symptoms. If present, any observed changes in venous pulsatility and drainage route were to be documented for further comparison. To monitor migraine symptoms response, the secondary outcomes included patient reported outcomes to measure any related change in Health Related Quality of Life (HRQoL), similarly used in migraine research. Throughout the study, subjects maintained headache diaries documenting the decrease (or increase) in the number of headache days, intensity, and medication used.

 

Conducting this observational case series, pilot study, allowed for additional investigation into aforementioned physiologic effects in further development of a working hypothesis into the pathophysiology of an atlas misalignment. Data required for estimation of statistically significant subject sample sizes and resolving procedural challenges will provide needed information for developing a refined protocol to conduct a blinded, placebo controlled migraine trial using the NUCCA correction intervention.

 

Methods

 

This research maintained compliance with the Helsinki Declaration for research on human subjects. The University of Calgary and Alberta Health Services Conjoint Health Research Ethics Board approved the study protocol and subject informed consent form, Ethics ID: E-24116. ClinicalTrials.gov assigned the number NCT01980927 after registration of this study (clinicaltrials.gov/ct2/show/NCT01980927).

 

Subject recruitment and screening occurred at the Calgary Headache Assessment and Management Program (CHAMP), a neurology-based specialist referral clinic (see Figure 1, Table 1). CHAMP evaluates patients resistant to standard pharmacotherapy and medical treatment for migraine headache that no longer provides migraine symptom relief. Family and primary care physicians referred potential study subjects to CHAMP making advertising unnecessary.

 

Figure 1 Subject Disposition and Study Flow

Figure 1: Subject disposition and study flow (n = 11). GSA: Gravity Stress Analyzer. HIT-6: Headache Impact Test-6. HRQoL: Health Related Quality of Life. MIDAS: Migraine Disability Assessment Scale. MSQL: Migraine-Specific Quality of Life Measure. NUCCA: National Upper Cervical Chiropractic Association. PC-MRI: Phase Contrast Magnetic Resonance Imaging. VAS: Visual Analog Scale.

 

Table 1 Subject Inclusion and Exclusion Criteria

Table 1: Subject inclusion/exclusion criteria. Potential subjects, na�ve to upper cervical chiropractic care, demonstrated between ten and twenty-six headache days per month self-reported over the previous four months. Requisite was at least eight headache days per month, where intensity reached at least four, on a zero to ten Visual Analog Scale (VAS) pain scale.

 

Study inclusion required volunteers, between the ages of 21 and 65 years, that satisfy specific diagnostic criteria for migraine headache. A neurologist with several decades of migraine experience screened applicants utilizing the International Classification of Headache Disorders (ICHD-2) for study inclusion [20]. Potential subjects, na�ve to upper cervical chiropractic care, must have demonstrated through self-report between ten and twenty-six headache days per month over the previous four months. At least eight headache days per month had to reach an intensity of at least four on a zero to ten VAS pain scale, unless treated successfully with a migraine-specific medication. At least four separate headache episodes per month separated by at least a 24-hour pain-free interval were required.

 

Significant head or neck trauma occurring within one year prior to study entry excluded candidates. Further exclusion criteria included acute medication overuse, a history of claustrophobia, cardiovascular or cerebrovascular disease, or any CNS disorder other than migraine. Table 1 describes the complete inclusion and exclusion criteria considered. Using an experienced board certified neurologist to screen potential subjects while adhering to the ICHD-2 and guided by the inclusion/exclusion criteria, the exclusion of subjects with other sources of headache such as muscular tension and medication overuse rebound headache would increase the likelihood of successful subject recruitment.

 

Those meeting initial criteria signed informed consent and then completed a baseline Migraine Disability Assessment Scale (MIDAS). The MIDAS requires twelve weeks to demonstrate clinically significant change [21]. This allowed adequate time to pass to discern any possible changes. Over the next 28 days, candidates recorded a headache diary providing baseline data while confirming the number of headache days and intensity required for inclusion. After the four weeks, the diary check diagnostic substantiation permitted administration of remaining baseline HRQoL measures:

 

  1. Migraine-Specific Quality of Life Measure (MSQL) [22],
  2. Headache Impact Test-6 (HIT-6) [23],
  3. Subject current global assessment of headache pain (VAS).

 

Referral to the NUCCA practitioner, to determine presence of atlas misalignment, confirmed need for intervention finalizing a subject’s study inclusion?exclusion. Absence of atlas misalignment indicators excluded candidates. After scheduling appointments for NUCCA intervention and care, qualified subjects obtained baseline PC-MRI measures. Figure 1 summarizes subject disposition throughout the study.

 

The initial NUCCA intervention required three consecutive visits: (1) Day One, atlas misalignment assessment, before-correction radiographs; (2) Day Two, NUCCA correction with after-correction assessment with radiographs; and (3) Day Three, after-correction reassessment. Follow-up care occurred weekly for four weeks, then every two weeks for the remainder of the study period. At each NUCCA visit, subjects completed a current assessment of headache pain (please rate your headache pain on average over the past week) using a straight edge and pencil in marking a 100?mm line (VAS). One week after the initial intervention, subjects completed a �Possible Reaction to Care� questionnaire. This assessment has past been used for successfully monitoring adverse events related to various upper cervical correction procedures [24].

 

At week four, PC-MRI data were obtained and subjects completed an MSQL and HIT-6. End of study PC-MRI data were collected at week eight followed by a neurologist exit interview. Here, subjects completed final MSQOL, HIT-6, MIDAS, and VAS outcomes and headache diaries were collected.

 

At the week-8 neurologist visit, two willing subjects were offered a long-term follow-up opportunity for a total study period of 24 weeks. This involved further NUCCA reassessment monthly for 16 weeks after completion of the initial 8-week study. The purpose of this follow-up was to help determine if headache improvement continued contingent upon maintenance of atlas alignment while observing for any long-term effect of NUCCA care on ICCI. Subjects desiring to participate signed a second informed consent for this phase of study and continued monthly NUCCA care. At the end of 24 weeks from the original atlas intervention, the fourth PC-MRI imaging study occurred. At the neurologist exit interview, final MSQOL, HIT-6, MIDAS, and VAS outcomes and headache diaries were collected.

 

The same NUCCA procedure as previously reported was followed using the established protocol and standards of care developed through NUCCA Certification for assessment and atlas realignment or correction of the ASC (see Figures ?Figures22�5) [2, 13, 25]. Assessment for the ASC includes screening for functional leg-length inequality with the Supine Leg Check (SLC) and examination of postural symmetry using the Gravity Stress Analyzer (Upper Cervical Store, Inc., 1641 17 Avenue, Campbell River, BC, Canada V9W 4L5) (see Figures ?Figures22 and 3(a)�3(c)) [26�28]. If SLC and postural imbalances are detected, a three-view radiographic exam is indicated to determine the multidimensional orientation and degree of craniocervical misalignment [29, 30]. A thorough radiographic analysis provides information to determine a subject specific, optimal atlas correction strategy. The clinician locates anatomic landmarks from the three-view series, measuring structural and functional angles that have deviated from established orthogonal standards. The degree of misalignment and atlas orientation are then revealed in three dimensions (see Figures 4(a)�4(c)) [2, 29, 30]. Radiographic equipment alignment, reduction of collimator port size, high-speed film-screen combinations, special filters, specialized grids, and lead shielding minimize subject radiation exposure. For this study, average total measured Entrance Skin Exposure to subjects from the before-after-correction radiographic series was 352 millirads (3.52 millisieverts).

 

Figure 2 Supine Leg Check Screening Test SLC

Figure 2: Supine Leg Check Screening Test (SLC). Observation of an apparent �short leg� indicates possible atlas misalignment. These appear even.

 

Figure 3 Gravity Stress Analyzer GSA

Figure 3: Gravity Stress Analyzer (GSA). (a) Device determines postural asymmetry as a further indicator of atlas misalignment. Positive findings in the SLC and GSA indicate need for NUCCA radiographic series. (b) Balanced patient with no postural asymmetry. (c) Hip calipers used to measure pelvis asymmetry.

 

Figure 4 NUCCA Radiograph Series

Figure 4: NUCCA radiograph series. These films are used to determine atlas misalignment and developing a correction strategy. After-correction radiographs or postfilms ensure the best correction has been made for that subject.

 

Figure 5 Making a NUCCA Correction

Figure 5: Making a NUCCA correction. The NUCCA practitioner delivers a triceps pull adjustment. The practitioner’s body and hands are aligned to deliver an atlas correction along an optimal force vector using information obtained from radiographs.

 

The NUCCA intervention involves a manual correction of the radiographically measured misalignment in the anatomical structure between the skull, atlas vertebra, and cervical spine. Utilizing biomechanical principles based on a lever system, the doctor develops a strategy for proper

 

  1. subject positioning,
  2. practitioner stance,
  3. force vector to correct the atlas misalignment.

 

Subjects are placed on a side-posture table with the head specifically braced using a mastoid support system. Application of the predetermined controlled force vector for the correction realigns the skull to the atlas and neck to the vertical axis or center of gravity of the spine. These corrective forces are controlled in depth, direction, velocity, and amplitude, producing an accurate and precise reduction of the ASC.

 

Using the pisiform bone of the contact hand, the NUCCA practitioner contacts the atlas transverse process. The other hand encircles the wrist of the contact hand, to control the vector while maintaining the depth of force generated in application of the �triceps pull� procedure (see Figure 5) [3]. By understanding spinal biomechanics, the practitioner’s body and hands are aligned to produce an atlas correction along the optimal force vector. The controlled, nonthrusting force is applied along the predetermined reduction pathway. It is specific in its direction and depth to optimize the ASC reduction assuring no activation in the reactive forces of the neck muscles in response to the biomechanical change. It is understood that an optimal reduction of the misalignment promotes long-term maintenance and stability of spinal alignment.

 

Following a short rest period, an after-assessment procedure, identical to the initial evaluation, is performed. A postcorrection radiograph examination uses two views to verify return of the head and cervical spine into optimum orthogonal balance. Subjects are educated in ways to preserve their correction, thus preventing another misalignment.

 

Subsequent NUCCA visits were comprised of headache diary checks and a current assessment of headache pain (VAS). Leg length inequality and excessive postural asymmetry were used in determining the need for another atlas intervention. The objective for optimal improvement is for the subject to maintain the realignment for as long as possible, with the fewest number of atlas interventions.

 

In a PC-MRI sequence, contrast media are not used. PC-MRI methods collected two data sets with different amounts of flow sensitivity acquired by relating gradient pairs, which sequentially dephase and rephase spins during the sequence. The raw data from the two sets are subtracted to calculate a flow rate.

 

An on-site visit by the MRI Physicist provided training for the MRI Technologist and a data transfer procedure was established. Several practice scans and data transfers were performed to ensure data collection succeeded without challenges. A 1.5-tesla GE 360 Optima MR scanner (Milwaukee, WI) at the study imaging center (EFW Radiology, Calgary, Alberta, Canada) was used in imaging and data collection. A 12-element phased array head coil, 3D magnetization-prepared rapid-acquisition gradient echo (MP-RAGE) sequence was used in anatomy scans. Flow sensitive data were acquired using a parallel acquisition technique (iPAT), acceleration factor 2.

 

To measure blood flow to and from the skull base, two retrospectively gated, velocity-encoded cine-phase-contrast scans were performed as determined by individual heart rate, collecting thirty-two images over a cardiac cycle. A high-velocity encoding (70?cm/s) quantified high-velocity blood flow perpendicular to the vessels at the C-2 vertebra level includes the internal carotid arteries (ICA), vertebral arteries (VA), and internal jugular veins (IJV). Secondary venous flow data of vertebral veins (VV), epidural veins (EV), and deep cervical veins (DCV) were acquired at the same height using a low-velocity encoding (7�9?cm/s) sequence.

 

Subject data were identified by Subject Study ID and imaging study date. The study neuroradiologist reviewed MR-RAGE sequences to rule out exclusionary pathologic conditions. Subject identifiers were then removed and assigned a coded ID permitting transfer via a secured tunnel IP protocol to the physicist for analysis. Using proprietary software volumetric blood, Cerebrospinal Fluid (CSF) flow rate waveforms and derived parameters were determined (MRICP version 1.4.35 Alperin Noninvasive Diagnostics, Miami, FL).

 

Using the pulsatility-based segmentation of lumens, time-dependent volumetric flow rates were calculated by integrating the flow velocities inside the luminal cross-sectional areas over all thirty-two images. Mean flow rates were obtained for the cervical arteries, primary venous drainage, and secondary venous drainage pathways. Total cerebral blood flow was obtained by summation of these mean flow rates.

 

A simple definition of compliance is a ratio of volume and pressure changes. Intracranial compliance is calculated from the ratio of the maximal (systolic) intracranial volume change (ICVC) and pressure fluctuations during the cardiac cycle (PTP-PG). Change in ICVC is obtained from momentary differences between volumes of blood and CSF entering and exiting the cranium [5, 31]. Pressure change during the cardiac cycle is derived from the change in the CSF pressure gradient, which is calculated from the velocity-encoded MR images of the CSF flow, using the Navier-Stokes relationship between derivatives of velocities and the pressure gradient [5, 32]. An intracranial compliance index (ICCI) is calculated from the ratio of ICVC and pressure changes [5, 31�33].

 

Statistical analysis considered several elements. ICCI data analysis involved a one-sample Kolmogorov-Smirnov test revealing a lack of normal distribution in the ICCI data, which were therefore described using the median and interquartile range (IQR). Differences between baseline and follow-up were to be examined using a paired t-test.

 

NUCCA assessments data were described using mean, median, and interquartile range (IQR). Differences between baseline and follow-up were examined using a paired t-test.

 

Depending on the outcome measure, baseline, week four, week eight, and week twelve (MIDAS only) follow-up values were described using the mean and standard deviation. MIDAS data collected at initial neurologist screening had one follow-up score at the end of twelve weeks.

 

Differences from baseline to each follow-up visit were tested using a paired t-test. This resulted in numerous p values from two follow-up visits for each outcome except the MIDAS. Since one purpose of this pilot is to provide estimates for future research, it was important to describe where differences occurred, rather than to use a one-way ANOVA to arrive at a single p value for each measure. The concern with such multiple comparisons is the increase in Type I error rate.

 

To analyze the VAS data, each subject scores were examined individually and then with a linear regression line that adequately fits the data. Use of a multilevel regression model with both random intercepts and random slope provided an individual regression line fitted for each patient. This was tested against a random intercept-only model, which fits a linear regression line with a common slope for all subjects, while intercept terms are allowed to vary. The random coefficient model was adopted, as there was no evidence that random slopes significantly improved the fit to the data (using a likelihood ratio statistic). To illustrate the variation in the intercepts but not in the slope, the individual regression lines were graphed for each patient with an imposed average regression line on top.

 

Results

 

From initial neurologist screening, eighteen volunteers were eligible for inclusion. After completion of baseline headache diaries, five candidates did not meet inclusion criteria. Three lacked the required headache days on baseline diaries to be included, one had unusual neurological symptoms with persistent unilateral numbness, and another was taking a calcium channel blocker. The NUCCA practitioner found two candidates ineligible: one lacking an atlas misalignment and the second with a Wolff-Parkinson-White condition and severe postural distortion (39�) with recent involvement in a severe high impact motor vehicle accident with whiplash (see Figure 1).

 

Eleven subjects, eight females and three males, average age forty-one years (range 21�61 years), qualified for inclusion. Six subjects presented chronic migraine, reporting fifteen or more headache days a month, with a total eleven-subject mean of 14.5 headache days a month. Migraine symptom duration ranged from two to thirty-five years (mean twenty-three years). All medications were maintained unchanged for the study duration to include their migraine prophylaxis regimens as prescribed.

 

Per exclusion criteria, no subjects included received a diagnosis of headache attributed to traumatic injury to the head and neck, concussion, or persistent headache attributed to whiplash. Nine subjects reported a very remote past history, greater than five years or more (average of nine years) prior to neurologist screen. This included sports-related head injuries, concussion, and/or whiplash. Two subjects indicated no prior head or neck injury (see Table 2).

 

Table 2 Subject Intracranial Compliance Index ICCI Data

Table 2: Subject intracranial compliance index (ICCI) data (n = 11). PC-MRI6 acquired ICCI1 data reported at baseline, week four, and week eight following NUCCA5 intervention. Bolded rows signify subject with secondary venous drainage route. MVA or mTBI occurred at least 5 years prior to study inclusion, average 10 years.

 

Individually, five subjects demonstrated an increase in ICCI, three subject’s values remained essentially the same, and three showed a decrease from baseline to end of study measurements. Overall changes in intracranial compliance are seen in Table 2 and Figure 8. The median (IQR) values of ICCI were 5.6 (4.8, 5.9) at baseline, 5.6 (4.9, 8.2) at week four, and 5.6 (4.6, 10.0) at week eight. Differences were not statistically different. The mean difference between baseline and week four was ?0.14 (95% CI ?1.56, 1.28), p = 0.834, and between baseline and week eight was 0.93 (95% CI ?0.99, 2.84), p = 0.307. These two subject’s 24-week ICCI study results are seen in Table 6. Subject 01 displayed an increasing trend in ICCI from 5.02 at baseline to 6.69 at week 24, whereas at week 8, results were interpreted as consistent or remaining the same. Subject 02 demonstrated a decreasing trend in ICCI from baseline of 15.17 to 9.47 at week 24.

 

Figure 8 Study ICCI Data Compared to Previously Reported Data in the Literature

Figure 8: Study ICCI data compared to previously reported data in the literature. The MRI time values are fixed at baseline, week 4, and week 8 after intervention. This study’s baseline values fall similar to the data reported by Pomschar on subjects presenting only with mTBI.

 

Table 6 24 Week Intracranial Compliance Index ICCI Data

Table 6: 24-week ICCI findings showing an increasing trend in subject 01 whereas at end of study (week 8), results were interpreted as consistent or remaining the same. Subject 02 continued to show a decreasing trend in ICCI.

 

Table 3 reports changes in NUCCA assessments. The mean difference from before to after the intervention is as follows: (1) SLC: 0.73 inches, 95% CI (0.61, 0.84) (p < 0.001); (2) GSA: 28.36 scale points, 95% CI (26.01, 30.72) (p < 0.001); (3) Atlas Laterality: 2.36 degrees, 95% CI (1.68, 3.05) (p < 0.001); and (4) Atlas Rotation: 2.00 degrees, 95% CI (1.12, 2.88) (p < 0.001). This would indicate that a probable change occurred following the atlas intervention as based on subject assessment.

 

Table 3 Descriptive Statistics of NUCCA Assessments

Table 3: Descriptive statistics [mean, standard deviation, median, and interquartile range (IQR2)] of NUCCA1 assessments before-after initial intervention (n = 11).

 

Headache diary results are reported in Table 4 and Figure 6. At baseline subjects had mean 14.5 (SD = 5.7) headache days per 28-day month. During the first month following NUCCA correction, mean headache days per month decreased by 3.1 days from baseline, 95% CI (0.19, 6.0), p = 0.039, to 11.4. During the second month headache days decreased by 5.7 days from baseline, 95% CI (2.0, 9.4), p = 0.006, to 8.7 days. At week eight, six of the eleven subjects had a reduction of >30% in headache days per month. Over 24 weeks, subject 01 reported essentially no change in headache days while subject 02 had a reduction of one headache day a month from study baseline of seven to end of study reports of six days.

 

Figure 6 Headache Days and Headache Pain Intensity from Diary

Figure 6: Headache days and headache pain intensity from diary (n = 11). (a) Number of headache days per month. (b) Average headache intensity (on headache days). Circle indicates the mean and the bar indicates the 95% CI. Circles are individual subject scores. A significant decrease in headache days per month was noticed at four weeks, almost doubling at eight weeks. Four subjects (#4, 5, 7, and 8) exhibited a greater than 20% decrease in headache intensity. Concurrent medication use may explain the small decrease in headache intensity.

 

At baseline, mean headache intensity on days with headache, on a scale of zero to ten, was 2.8 (SD = 0.96). Mean headache intensity showed no statistically significant change at four (p = 0.604) and eight (p = 0.158) weeks. Four subjects (#4, 5, 7, and 8) exhibited a greater than 20% decrease in headache intensity.

 

Quality of life and headache disability measures are seen in Table 4. The mean HIT-6 score at baseline was 64.2 (SD = 3.8). At week four after NUCCA correction, mean decrease in scores was 8.9, 95% CI (4.7, 13.1), p = 0.001. Week-eight scores, compared to baseline, revealed mean decrease by 10.4, 95% CI (6.8, 13.9), p = 0.001. In the 24-week group, subject 01 showed a decrease of 10 points from 58 at week 8 to 48 at week 24 while subject 02 decreased 7 points from 55 at week 8 to 48 at week 24 (see Figure 9).

 

Figure 9 24 Week HIT 6 Scores in Long Term Follow Up Subjects

Figure 9: 24-week HIT-6 scores in long-term follow-up subjects. Monthly scores continued to decrease after week 8, end of first study. Based on Smelt et al. criteria, it can be interpreted that a within-person minimally important change occurred between week 8 and week 24. HIT-6: Headache Impact Test-6.

 

MSQL mean baseline score was 38.4 (SD = 17.4). At week four after correction, mean scores for all eleven subjects increased (improved) by 30.7, 95% CI (22.1, 39.2), p < 0.001. By week eight, end of study, mean MSQL scores had increased from baseline by 35.1, 95% CI (23.1, 50.0), p < 0.001, to 73.5. The follow-up subjects continued to show some improvement with increasing scores; however, many scores plateaued remaining the same since week 8 (see Figures 10(a)�10(c)).

 

Figure 10 24 Week MSQL Scores in Long Term Follow p Subjects

Figure 10: ((a)�(c)) 24-week MSQL scores in long-term follow-up subjects. (a) Subject 01 has essentially plateaued after week 8 throughout to end of the second study. Subject 02 shows scores increasing over time demonstrating minimally important differences based on Cole et al. criteria by week 24. (b) Subject scores seem to peak by week 8 with both subjects showing similar scores reported at week 24. (c) Subject 2 scores remain consistent throughout the study while subject 01 shows steady improvement from baseline to the end of week 24. MSQL: Migraine-Specific Quality of Life Measure.

 

Mean MIDAS score at baseline was 46.7 (SD = 27.7). At two months after NUCCA correction (three months following baseline), the mean decrease in subject’s MIDAS scores was 32.1, 95% CI (13.2, 51.0), p = 0.004. The follow-up subjects continued to show improvement with decreasing scores with intensity showing minimal improvement (see Figures 11(a)�11(c)).

 

Figure 11 24 Week MIDAS Scores in Long Term Follow Up Subjects

Figure 11: 24-week MIDAS scores in long-term follow-up subjects. (a) Total MIDAS scores continued a decreasing trend over the 24-week study period. (b) Intensity scores continued improvement. (c) While 24-week frequency was higher than at week 8, improvement is observed when compared to baseline. MIDAS: Migraine Disability Assessment Scale.

 

Assessment of current headache pain from VAS scale data is seen in Figure 7. The multilevel linear regression model showed evidence of a random effect for the intercept (p < 0.001) but not for the slope (p = 0.916). Thus, the adopted random intercept model estimated a different intercept for each patient but a common slope. The estimated slope of this line was ?0.044, 95% CI (?0.055, ?0.0326), p < 0.001, indicating that there was a significant decrease in the VAS score of 0.44 per 10 days after baseline (p < 0.001). The mean baseline score was 5.34, 95% CI (4.47, 6.22). The random effects analysis showed substantial variation in the baseline score (SD = 1.09). As the random intercepts are normally distributed, this indicates that 95% of such intercepts lie between 3.16 and 7.52 providing evidence of substantial variation in the baseline values across patients. VAS scores continued showing improvement in the 24-week two-subject follow-up group (see Figure 12).

 

Figure 7 Subject Global Assessment of Headache VAS

Figure 7: Subject global assessment of headache (VAS) (n = 11). There was substantial variation in baseline scores across these patients. The lines show individual linear fit for each of eleven patients. The thick dotted black line represents the average linear fit across all eleven patients. VAS: Visual Analog Scale.

 

Figure 12 24 Week Follow Up Group Global Assessment of Headache VAS

Figure 12: 24-week follow-up group global assessment of headache (VAS). When subjects were queried, �please rate your headache pain on average over the past week� VAS scores continued showing improvement in the 24-week two-subject follow-up group.

 

The most obvious reaction to the NUCCA intervention and care reported by ten subjects was mild neck discomfort, rated an average of three out of ten on pain assessment. In six subjects, pain began more than twenty-four hours after the atlas correction, lasting more than twenty-four hours. No subject reported any significant effect on their daily activities. All subjects reported satisfaction with NUCCA care after one week, median score, ten, on a zero to ten rating scale.

 

Dr Jimenez White Coat

Dr. Alex Jimenez’s Insight

“I’ve been experiencing migraine headaches for several years now. Is there a reason for my head pain? What can I do to decrease or get rid of my symptoms?”�Migraine headaches are believed to be a complex form of head pain, however, the reason for them is much the same as any other type of headache. A traumatic injury to the cervical spine, such as that of whiplash from an automobile accident or a sports injury, can cause a misalignment in the neck and upper back, which may lead to migraine. An improper posture can also cause neck issues which could lead to head and neck pain. A healthcare professional who specializes in spinal health issues can diagnose the source of your migraine headaches. Furthermore, a qualified and experienced specialist can perform spinal adjustments as well as manual manipulations to help correct any misalignments of the spine which could be causing the symptoms. The following article summarizes a case study based on the improvement of symptoms after atlas vertebrae realignment in participants with migraine.

 

Discussion

 

In this limited cohort of eleven migraine subjects, there was no statistically significant change in ICCI (primary outcome) after the NUCCA intervention. However, a significant change in HRQoL secondary outcomes did occur as summarized in Table 5. The consistency in the magnitude and direction of improvement across these HRQoL measures indicates confidence in enhancement of headache health over the two-month study following the 28-day baseline period.

 

Table 5 Summary Comparison of Measured Outcomes

Table 5: Summary Comparison of Measured Outcomes

 

Based on the case study results, this investigation hypothesized a significant increase in ICCI after the atlas intervention which was not observed. Use of PC-MRI allows quantification of the dynamic relationship between arterial inflow, venous outflow, and CSF flow between the cranium and the spinal canal [33]. Intracranial compliance index (ICCI) measures the brain’s ability to respond to incoming arterial blood during systole. Interpretation of this dynamic flow is represented by a monoexponential relationship existing between CSF volume and CSF pressure. With increased or higher intracranial compliance, also defined as good compensatory reserve, the incoming arterial blood can be accommodated by the intracranial contents with a smaller change in intracranial pressure. While a change in intracranial volume or pressure could occur, based on the exponential nature of the volume-pressure relationship, a change in after-intervention ICCI may not be realized. An advanced analysis of the MRI data and further study are required for pinpointing practical quantifiable parameters to use as an objective outcome sensitive for documenting a physiologic change following atlas correction.

 

Koerte et al. reports of chronic migraine patients demonstrate a significantly higher relative secondary venous drainage (paraspinal plexus) in the supine position when compared to age- and gender-matched controls [34]. Four study subjects exhibited a secondary venous drainage with three of those subjects demonstrating notable increase in compliance after intervention. The significance is unknown without further study. Similarly, Pomschar et al. reported that subjects with mild traumatic brain injury (mTBI) demonstrate an increased drainage through the secondary venous paraspinal route [35]. The mean intracranial compliance index appears significantly lower in the mTBI cohort when compared to controls.

 

Some perspective may be gained in comparison of this study’s ICCI data to previously reported normal subjects and those with mTBI seen in Figure 8 [5, 35]. Limited by the small number of subjects studied, the significance these study’s findings may have in relation to Pomschar et al. remains unknown, offering only speculation of possibilities for future exploration. This is further complicated by the inconsistent ICCI change observed in the two subjects followed for 24 weeks. Subject two with a secondary drainage pattern exhibited a decrease in ICCI following intervention. A larger placebo controlled trial with a statistically significant subject sample size could possibly demonstrate a definitive objectively measured physiologic change after application of the NUCCA correction procedure.

 

HRQoL measures are used clinically to assess the effectiveness of a treatment strategy to decrease pain and disability related to migraine headache. It is expected that an effective treatment improves patient perceived pain and disability measured by these instruments. All HRQoL measures in this study demonstrated significant and substantial improvement by week four following the NUCCA intervention. From week four to week eight only small improvements were noted. Again, only small improvements were noted in the two subjects followed for 24 weeks. While this study was not intended to demonstrate causation from the NUCCA intervention, the HRQoL results create compelling interest for further study.

 

From the headache diary, a significant decrease in headache days per month was noticed at four weeks, almost doubling at eight weeks. However, significant differences in headache intensity over time were not discernable from this diary data (see Figure 5). While the number of headaches decreased, subjects still used medication to maintain headache intensity at tolerable levels; hence, it is supposed that a statistically significant difference in headache intensity could not be determined. Consistency in the headache day numbers occurring in week 8 in the follow-up subjects could guide future study focus in determining when maximum improvement occurs to help in establishing a NUCCA standard of migraine care.

 

Clinically relevant change in the HIT-6 is important for completely understanding observed outcomes. A clinically meaningful change for an individual patient has been defined by the HIT-6 user guide as ?5 [36]. Coeytaux et al., using four different analysis methods, suggest that a between-group difference in HIT-6 scores of 2.3 units over time may be considered clinically significant [37]. Smelt et al. studied primary care migraine patient populations in developing suggested recommendations using HIT-6 score changes for clinical care and research [38]. Dependent on consequences resulting from false positives or negatives, within-person minimally important change (MIC) using a �mean change approach� was estimated to be 2.5 points. When using the �receiver operating characteristic (ROC) curve analysis� a 6-point change is needed. Recommended between-group minimally important difference (MID) is 1.5 [38].

 

Using the �mean change approach,� all subjects but one reported a change (decrease) greater than ?2.5. The �ROC analyses� also demonstrated improvement by all subjects but one. This �one subject� was a different person in each comparison analysis. Based on Smelt et al. criteria, the follow-up subjects continued to demonstrate within-person minimally important improvement as seen in Figure 10.

 

All subjects but two showed improvement on the MIDAS score between baseline and three-month results. The magnitude of the change was proportional to the baseline MIDAS score, with all subjects but three reporting an overall fifty percent or greater change. The follow-up subjects continued to show improvement as seen in continued decrease in scores by week 24; see Figures 11(a)�11(c).

 

Use of the HIT-6 and MIDAS together as a clinical outcome may provide a more complete assessment of headache-related disability factors [39]. The differences between the two scales can predict disability from headache pain intensity and headache frequency, by providing more information on factors related to the reported changes than either outcome used alone. While the MIDAS appears to change more by headache frequency, headache intensity seems to affect HIT-6 score more than the MIDAS [39].

 

How migraine headache affects and limits patient perceived daily functioning is reported by the MSQL v. 2.1, across three 3 domains: role restrictive (MSQL-R), role preventive (MSQL-P), and emotional functioning (MSQL-E). An increase in scores indicates improvement in these areas with values ranging from 0 (poor) to 100 (best).

 

MSQL scales reliability evaluation by Bagley et al. report results to be moderately to highly correlated with HIT-6 (r = ?0.60 to ?0.71) [40]. Study by Cole et al. reports minimally important differences (MID) clinical change for each domain: MSQL-R = 3.2, MSQL-P = 4.6, and MSQL-E = 7.5 [41]. Results from the topiramate study report individual minimally important clinical (MIC) change: MSQL-R = 10.9, MSQL-P = 8.3, and MSQL-E = 12.2 [42].

 

All subjects except one experienced an individual minimally important clinical change for MSQL-R of greater than 10.9 by the week-eight follow-up in MSQL-R. All but two subjects reported changes of more than 12.2 points in MSQL-E. Improvement in MSQL-P scores increased by ten points or more in all subjects.

 

Regression analysis of VAS ratings over time showed a significant linear improvement over the 3-month period. There was substantial variation in baseline scores across these patients. Little to no variation was observed in the rate of improvement. This trend appears to be the same in the subjects studied for 24 weeks as seen in Figure 12.

 

Dr Jimenez works on wrestler's neck

 

Many studies using pharmaceutical intervention have shown a substantial placebo effect in patients from migrainous populations [43]. Determining possible migraine improvement over six months, using another intervention as well as no intervention, is important for any comparison of results. The investigation into placebo effects generally accepts that placebo interventions do provide symptomatic relief but do not modify pathophysiologic processes underlying the condition [44]. Objective MRI measures may help in revealing such a placebo effect by demonstrating a change in physiologic measurements of flow parameters occurring after a placebo intervention.

 

Use of a three-tesla magnet for MRI data collection would increase the reliability of the measurements by increasing the amount of data used to make the flow and ICCI calculations. This is one of the first investigations using change in ICCI as an outcome in evaluating an intervention. This creates challenges in interpretation of MRI acquired data to base conclusions or further hypothesis development. Variability in relationships between blood flow to and from the brain, CSF flow, and heart rate of these subject-specific parameters has been reported [45]. Variations observed in a small three-subject repeated measures study have led to conclusions that information gathered from individual cases be interpreted with caution [46].

 

The literature further reports in larger studies significant reliability in collecting these MRI acquired volumetric flow data. Wentland et al. reported that measurements of CSF velocities in human volunteers and of sinusoidally fluctuating phantom velocities did not differ significantly between two MRI techniques used [47]. Koerte et al. studied two cohorts of subjects imaged in two separate facilities with different equipment. They reported that intraclass correlation coefficients (ICC) demonstrated a high intra- and interrater reliability of PC-MRI volumetric flow rate measurements remaining independent of equipment used and skill-level of the operator [48]. While anatomic variation exists between subjects, it has not prevented studies of larger patient populations in describing possible �normal� outflow parameters [49, 50].

 

Being based solely on patient subjective perceptions, there are limitations in using patient reported outcomes [51]. Any aspect affecting a subject’s perception in their quality of life is likely to influence the outcome of any assessment used. Lack of outcome specificity in reporting symptoms, emotions, and disability also limits interpretation of results [51].

 

Imaging and MRI data analysis costs precluded use of a control group, limiting any generalizability of these results. A larger sample size would allow for conclusions based on statistical power and reduced Type I error. Interpretation of any significance in these results, while revealing possible trends, remains speculation at best. The big unknown persists in the likelihood that these changes are related to the intervention or to some other effect unknown to the investigators. These results do add to the body of knowledge of previously unreported possible hemodynamic and hydrodynamic changes after a NUCCA intervention, as well as changes in migraine HRQoL patient reported outcomes as observed in this cohort.

 

The values of collected data and analyses are providing information required for estimation of statistically significant subject sample sizes in further study. Resolved procedural challenges from conducting the pilot allow for a highly refined protocol to successfully accomplish this task.

 

In this study, the lack of robust increase in compliance may be understood by the logarithmic and dynamic nature of intracranial hemodynamic and hydrodynamic flow, allowing individual components comprising compliance to change while overall it did not. An effective intervention should improve subject perceived pain and disability related to migraine headache as measured by these HRQoL instruments used. These study results suggest that the atlas realignment intervention may be associated with reduction in migraine frequency, marked improvement in quality of life yielding significant reduction in headache-related disability as observed in this cohort. The improvement in HRQoL outcomes creates compelling interest for further study, to confirm these findings, especially with a larger subject pool and a placebo group.

 

Acknowledgments

 

The authors acknowledge Dr. Noam Alperin, Alperin Diagnostics, Inc., Miami, FL; Kathy Waters, Study Coordinator, and Dr. Jordan Ausmus, Radiography Coordinator, Britannia Clinic, Calgary, AB; Sue Curtis, MRI Technologist, Elliot Fong Wallace Radiology, Calgary, AB; and Brenda Kelly-Besler, RN, Research Coordinator, Calgary Headache Assessment and Management Program (CHAMP), Calgary, AB. Financial support is provided by (1) Hecht Foundation, Vancouver, BC; (2) Tao Foundation, Calgary, AB; (3) Ralph R. Gregory Memorial Foundation (Canada), Calgary, AB; and (4) Upper Cervical Research Foundation (UCRF), Minneapolis, MN.

 

Abbreviations

 

  • ASC: Atlas subluxation complex
  • CHAMP: Calgary Headache Assessment and Management Program
  • CSF: Cerebrospinal Fluid
  • GSA: Gravity Stress Analyzer
  • HIT-6: Headache Impact Test-6
  • HRQoL: Health Related Quality of Life
  • ICCI: Intracranial compliance index
  • ICVC: Intracranial volume change
  • IQR: Interquartile range
  • MIDAS: Migraine Disability Assessment Scale
  • MSQL: Migraine-Specific Quality of Life Measure
  • MSQL-E: Migraine-Specific Quality of Life Measure-Emotional
  • MSQL-P: Migraine-Specific Quality of Life Measure-Physical
  • MSQL-R: Migraine-Specific Quality of Life Measure-Restrictive
  • NUCCA: National Upper Cervical Chiropractic Association
  • PC-MRI: Phase Contrast Magnetic Resonance Imaging
  • SLC: Supine Leg Check
  • VAS: Visual Analog Scale.

 

Conflict of Interests

 

The authors declare that there are no financial or any other competing interests regarding the publication of this paper.

 

Authors’ Contribution

 

H. Charles Woodfield III conceived the study, was instrumental in its design, helped in coordination, and helped to draft the paper: introduction, study methods, results, discussion, and conclusion. D. Gordon Hasick screened subjects for study inclusion/exclusion, provided NUCCA interventions, and monitored all subjects on follow-up. He participated in study design and subject coordination, helping to draft the Introduction, NUCCA Methods, and Discussion of the paper. Werner J. Becker screened subjects for study inclusion/exclusion, participated in study design and coordination, and helped to draft the paper: study methods, results and discussion, and conclusion. Marianne S. Rose performed statistical analysis on study data and helped to draft the paper: statistical methods, results, and discussion. James N. Scott participated in study design, served as the imaging consultant reviewing scans for pathology, and helped to draft the paper: PC-MRI methods, results, and discussion. All authors read and approved the final paper.

 

In conclusion, the case study regarding the improvement of migraine headache symptoms following atlas vertebrae realignment demonstrated an increase in the primary outcome, however, the average results of the research study also demonstrated no statistical significance. Altogether, the case study concluded that patients who received atlas vertebrae realignment treatment experienced considerable improvement in symptoms with decreased headache days. Information referenced from the National Center for Biotechnology Information (NCBI). The scope of our information is limited to chiropractic as well as to spinal injuries and conditions. To discuss the subject matter, please feel free to ask Dr. Jimenez or contact us at 915-850-0900 .

 

Curated by Dr. Alex Jimenez

 

Green-Call-Now-Button-24H-150x150-2-3.png

 

Additional Topics: Neck Pain

 

Neck pain is a common complaint which can result due to a variety of injuries and/or conditions. According to statistics, automobile accident injuries and whiplash injuries are some of the most prevalent causes for neck pain among the general population. During an auto accident, the sudden impact from the incident can cause the head and neck to jolt abruptly back-and-forth in any direction, damaging the complex structures surrounding the cervical spine. Trauma to the tendons and ligaments, as well as that of other tissues in the neck, can cause neck pain and radiating symptoms throughout the human body.

 

blog picture of cartoon paperboy big news

 

IMPORTANT TOPIC: EXTRA EXTRA: A Healthier You!

 

OTHER IMPORTANT TOPICS: EXTRA: Sports Injuries? | Vincent Garcia | Patient | El Paso, TX Chiropractor

 

Blank
References
1. Magoun H. W. Caudal and cephalic influences of the brain stem reticular formation. Physiological Reviews. 1950;30(4):459�474. [PubMed]
2. Gregory R. Manual of Upper Cervical Analysis. Monroe, Mich, USA: National Upper Cervical Chiropractic Association; 1971.
3. Thomas M., editor. NUCCA Protocols and Perspectives. 1st. Monroe, Mich, USA: National Upper Cervical Chiropractic Association; 2002.
4. Grostic J. D. Dentate ligament-cord distortion hypothesis. Chiropractic Research Journal. 1988;1(1):47�55.
5. Alperin N., Sivaramakrishnan A., Lichtor T. Magnetic resonance imaging-based measurements of cerebrospinal fluid and blood flow as indicators of intracranial compliance in patients with Chiari malformation. Journal of Neurosurgery. 2005;103(1):46�52. doi: 10.3171/jns.2005.103.1.0046. [PubMed] [Cross Ref]
6. Czosnyka M., Pickard J. D. Monitoring and interpretation of intracranial pressure. Journal of Neurology, Neurosurgery and Psychiatry. 2004;75(6):813�821. doi: 10.1136/jnnp.2003.033126. [PMC free article] [PubMed] [Cross Ref]
7. Tobinick E., Vega C. P. The cerebrospinal venous system: anatomy, physiology, and clinical implications. MedGenMed: Medscape General Medicine. 2006;8(1, article 153) [PubMed]
8. Eckenhoff J. E. The physiologic significance of the vertebral venous plexus. Surgery Gynecology and Obstetrics. 1970;131(1):72�78. [PubMed]
9. Beggs C. B. Venous hemodynamics in neurological disorders: an analytical review with hydrodynamic analysis. BMC Medicine. 2013;11, article 142 doi: 10.1186/1741-7015-11-142. [PMC free article] [PubMed] [Cross Ref]
10. Beggs C. B. Cerebral venous outflow and cerebrospinal fluid dynamics. Veins and Lymphatics. 2014;3(3):81�88. doi: 10.4081/vl.2014.1867. [Cross Ref]
11. Cassar-Pullicino V. N., Colhoun E., McLelland M., McCall I. W., El Masry W. Hemodynamic alterations in the paravertebral venous plexus after spinal injury. Radiology. 1995;197(3):659�663. doi: 10.1148/radiology.197.3.7480735. [PubMed] [Cross Ref]
12. Damadian R. V., Chu D. The possible role of cranio-cervical trauma and abnormal CSF hydrodynamics in the genesis of multiple sclerosis. Physiological Chemistry and Physics and Medical NMR. 2011;41(1):1�17. [PubMed]
13. Bakris G., Dickholtz M., Meyer P. M., et al. Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study. Journal of Human Hypertension. 2007;21(5):347�352. doi: 10.1038/sj.jhh.1002133. [PubMed] [Cross Ref]
14. Kumada M., Dampney R. A. L., Reis D. J. The trigeminal depressor response: a cardiovascular reflex originating from the trigeminal system. Brain Research. 1975;92(3):485�489. doi: 10.1016/0006-8993(75)90335-2. [PubMed] [Cross Ref]
15. Kumada M., Dampney R. A. L., Whitnall M. H., Reis D. J. Hemodynamic similarities between the trigeminal and aortic vasodepressor responses. The American Journal of Physiology�Heart and Circulatory Physiology. 1978;234(1):H67�H73. [PubMed]
16. Goadsby P. J., Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Annals of Neurology. 1993;33(1):48�56. doi: 10.1002/ana.410330109. [PubMed] [Cross Ref]
17. Goadsby P. J., Fields H. L. On the functional anatomy of migraine. Annals of Neurology. 1998;43(2, article 272) doi: 10.1002/ana.410430221. [PubMed] [Cross Ref]
18. May A., Goadsby P. J. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. Journal of Cerebral Blood Flow and Metabolism. 1999;19(2):115�127. [PubMed]
19. Goadsby P. J., Hargreaves R. Refractory migraine and chronic migraine: pathophysiological mechanisms. Headache. 2008;48(6):799�804. doi: 10.1111/j.1526-4610.2008.01157.x. [PubMed] [Cross Ref]
20. Olesen J., Bousser M.-G., Diener H.-C., et al. The international classification of headache disorders, 2nd edition (ICHD-II)�revision of criteria for 8.2 medication-overuse headache. Cephalalgia. 2005;25(6):460�465. doi: 10.1111/j.1468-2982.2005.00878.x. [PubMed] [Cross Ref]
21. Stewart W. F., Lipton R. B., Whyte J., et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology. 1999;53(5):988�994. doi: 10.1212/wnl.53.5.988. [PubMed] [Cross Ref]
22. Wagner T. H., Patrick D. L., Galer B. S., Berzon R. A. A new instrument to assess the long-term quality of life effects from migraine: development and psychometric testing of the MSQOL. Headache. 1996;36(8):484�492. doi: 10.1046/j.1526-4610.1996.3608484.x. [PubMed] [Cross Ref]
23. Kosinski M., Bayliss M. S., Bjorner J. B., et al. A six-item short-form survey for measuring headache impact: the HIT-6. Quality of Life Research. 2003;12(8):963�974. doi: 10.1023/a:1026119331193. [PubMed] [Cross Ref]
24. Eriksen K., Rochester R. P., Hurwitz E. L. Symptomatic reactions, clinical outcomes and patient satisfaction associated with upper cervical chiropractic care: a prospective, multicenter, cohort study. BMC Musculoskeletal Disorders. 2011;12, article 219 doi: 10.1186/1471-2474-12-219. [PMC free article] [PubMed] [Cross Ref]
25. National Upper Cervical Chiropractic Association. NUCCA Standards of Practice and Patient Care. 1st. Monroe, Mich, USA: National Upper Cervical Chiropractic Association; 1994.
26. Gregory R. A model for the supine leg check. Upper Cervical Monograph. 1979;2(6):1�5.
27. Woodfield H. C., Gerstman B. B., Olaisen R. H., Johnson D. F. Interexaminer reliability of supine leg checks for discriminating leg-length inequality. Journal of Manipulative and Physiological Therapeutics. 2011;34(4):239�246. doi: 10.1016/j.jmpt.2011.04.009. [PubMed] [Cross Ref]
28. Andersen R. T., Winkler M. The gravity stress analyzer for measuring spinal posture. Journal of the Canadian Chiropractic Association. 1983;2(27):55�58.
29. Eriksen K. Subluxation X-ray analysis. In: Eriksen K., editor. Upper Cervical Subluxation Complex�A Review of the Chiropractic and Medical Literature. 1st. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2004. pp. 163�203.
30. Zabelin M. X-ray analysis. In: Thomas M., editor. NUCCA: Protocols and Perspectives. 1st. Monroe: National Upper Cervical Chiropractic Association; 2002. p. p. 10-1-48.
31. Miyati T., Mase M., Kasai H., et al. Noninvasive MRI assessment of intracranial compliance in idiopathic normal pressure hydrocephalus. Journal of Magnetic Resonance Imaging. 2007;26(2):274�278. doi: 10.1002/jmri.20999. [PubMed] [Cross Ref]
32. Alperin N., Lee S. H., Loth F., Raksin P. B., Lichtor T. MR-intracranial pressure (ICP). A method to measure intracranial elastance and pressure noninvasively by means of MR imaging: baboon and human study. Radiology. 2000;217(3):877�885. doi: 10.1148/radiology.217.3.r00dc42877. [PubMed] [Cross Ref]
33. Raksin P. B., Alperin N., Sivaramakrishnan A., Surapaneni S., Lichtor T. Noninvasive intracranial compliance and pressure based on dynamic magnetic resonance imaging of blood flow and cerebrospinal fluid flow: review of principles, implementation, and other noninvasive approaches. Neurosurgical Focus. 2003;14(4, article E4) [PubMed]
34. Koerte I. K., Schankin C. J., Immler S., et al. Altered cerebrovenous drainage in patients with migraine as assessed by phase-contrast magnetic resonance imaging. Investigative Radiology. 2011;46(7):434�440. doi: 10.1097/rli.0b013e318210ecf5. [PubMed] [Cross Ref]
35. Pomschar A., Koerte I., Lee S., et al. MRI evidence for altered venous drainage and intracranial compliance in mild traumatic brain injury. PLoS ONE. 2013;8(2) doi: 10.1371/journal.pone.0055447.e55447 [PMC free article] [PubMed] [Cross Ref]
36. Bayliss M. S., Batenhorst A. S. The HIT-6 A User’s guide. Lincoln, RI, USA: QualityMetric Incorporated; 2002.
37. Coeytaux R. R., Kaufman J. S., Chao R., Mann J. D., DeVellis R. F. Four methods of estimating the minimal important difference scores were compared to establish a clinically significant change in Headache Impact Test. Journal of Clinical Epidemiology. 2006;59(4):374�380. doi: 10.1016/j.jclinepi.2005.05.010. [PubMed] [Cross Ref]
38. Smelt A. F. H., Assendelft W. J. J., Terwee C. B., Ferrari M. D., Blom J. W. What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patients. Cephalalgia. 2014;34(1):29�36. doi: 10.1177/0333102413497599. [PubMed] [Cross Ref]
39. Sauro K. M., Rose M. S., Becker W. J., et al. HIT-6 and MIDAS as measures of headache disability in a headache referral population. Headache. 2010;50(3):383�395. doi: 10.1111/j.1526-4610.2009.01544.x. [PubMed] [Cross Ref]
40. Bagley C. L., Rendas-Baum R., Maglinte G. A., et al. Validating migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52(3):409�421. doi: 10.1111/j.1526-4610.2011.01997.x. [PubMed] [Cross Ref]
41. Cole J. C., Lin P., Rupnow M. F. T. Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version 2.1. Cephalalgia. 2009;29(11):1180�1187. doi: 10.1111/j.1468-2982.2009.01852.x. [PubMed] [Cross Ref]
42. Dodick D. W., Silberstein S., Saper J., et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache. 2007;47(10):1398�1408. doi: 10.1111/j.1526-4610.2007.00950.x. [PubMed] [Cross Ref]
43. Hr�bjartsson A., G�tzsche P. C. Placebo interventions for all clinical conditions. Cochrane Database of Systematic Reviews. 2010;(1)CD003974 [PubMed]
44. Meissner K. The placebo effect and the autonomic nervous system: evidence for an intimate relationship. Philosophical Transactions of the Royal Society B: Biological Sciences. 2011;366(1572):1808�1817. doi: 10.1098/rstb.2010.0403. [PMC free article] [PubMed] [Cross Ref]
45. Marshall I., MacCormick I., Sellar R., Whittle I. Assessment of factors affecting MRI measurement of intracranial volume changes and elastance index. British Journal of Neurosurgery. 2008;22(3):389�397. doi: 10.1080/02688690801911598. [PubMed] [Cross Ref]
46. Raboel P. H., Bartek J., Andresen M., Bellander B. M., Romner B. Intracranial pressure monitoring: invasive versus non-invasive methods-A review. Critical Care Research and Practice. 2012;2012:14. doi: 10.1155/2012/950393.950393 [PMC free article] [PubMed] [Cross Ref]
47. Wentland A. L., Wieben O., Korosec F. R., Haughton V. M. Accuracy and reproducibility of phase-contrast MR imaging measurements for CSF flow. American Journal of Neuroradiology. 2010;31(7):1331�1336. doi: 10.3174/ajnr.A2039. [PMC free article] [PubMed] [Cross Ref]
48. Koerte I., Haberl C., Schmidt M., et al. Inter- and intra-rater reliability of blood and cerebrospinal fluid flow quantification by phase-contrast MRI. Journal of Magnetic Resonance Imaging. 2013;38(3):655�662. doi: 10.1002/jmri.24013. [PMC free article] [PubMed] [Cross Ref]
49. Stoquart-Elsankari S., Lehmann P., Villette A., et al. A phase-contrast MRI study of physiologic cerebral venous flow. Journal of Cerebral Blood Flow and Metabolism. 2009;29(6):1208�1215. doi: 10.1038/jcbfm.2009.29. [PubMed] [Cross Ref]
50. Atsumi H., Matsumae M., Hirayama A., Kuroda K. Measurements of intracranial pressure and compliance index using 1.5-T clinical MRI machine. Tokai Journal of Experimental and Clinical Medicine. 2014;39(1):34�43. [PubMed]
51. Becker W. J. Assessing health-related quality of life in patients with migraine. Canadian Journal of Neurological Sciences. 2002;29(supplement 2):S16�S22. doi: 10.1017/s031716710000189x. [PubMed] [Cross Ref]
Close Accordion
Chiropractic Spinal Manipulative Therapy for Migraine

Chiropractic Spinal Manipulative Therapy for Migraine

Headaches can be a real aggravating issue, especially if these begin to occur more frequently. Even more so, headaches can become a bigger problem when the common type of head pain becomes a migraine. Head pain is often a symptom resulting from an underlying injury and/or condition along the cervical spine, or upper back and neck. Fortunately, a variety of treatment methods are available to help treat headaches. Chiropractic care is a well-known alternative treatment option which is commonly recommended for neck pain, headaches and migraines. The purpose of the following research study is to determine the effectiveness of chiropractic spinal manipulative therapy for migraine.

Chiropractic Spinal Manipulative Therapy for Migraine: a Study Protocol of a Single-Blinded Placebo-Controlled Randomised Clinical Trial

 

Abstract

 

Introduction

 

Migraine affects 15% of the population, and has substantial health and socioeconomic costs. Pharmacological management is first-line treatment. However, acute and/or prophylactic medicine might not be tolerated due to side effects or contraindications. Thus, we aim to assess the efficacy of chiropractic spinal manipulative therapy (CSMT) for migraineurs in a single-blinded placebo-controlled randomised clinical trial (RCT).

 

Method and Analysis

 

According to the power calculations, 90 participants are needed in the RCT. Participants will be randomised into one of three groups: CSMT, placebo (sham manipulation) and control (usual non-manual management). The RCT consists of three stages: 1?month run-in, 3?months intervention and follow-up analyses at the end of the intervention and 3, 6 and 12?months. The primary end point is migraine frequency, while migraine duration, migraine intensity, headache index (frequency x duration x intensity) and medicine consumption are secondary end points. Primary analysis will assess a change in migraine frequency from baseline to the end of the intervention and follow-up, where the groups CSMT and placebo and CSMT and control will be compared. Owing to two group comparisons, p values below 0.025 will be considered statistically significant. For all secondary end points and analyses, a p value below 0.05 will be used. The results will be presented with the corresponding p values and 95% CIs.

 

Ethics and Dissemination

 

The RCT will follow the clinical trial guidelines from the International Headache Society. The Norwegian Regional Committee for Medical Research Ethics and the Norwegian Social Science Data Services have approved the project. Procedure will be conducted according to the declaration of Helsinki. The results will be published at scientific meetings and in peer-reviewed journals.

 

Trial Registration Number

 

NCT01741714.

Keywords: Statistics & Research Methods

 

Strengths and Limitations of this Study

 

  • The study will be the first three-armed manual therapy randomised clinical trial (RCT) assessing the efficacy of chiropractic spinal manipulative therapy versus placebo (sham manipulation) and control (continue usual pharmacological management without receiving manual intervention) for migraineurs.
  • Strong internal validity, since a single chiropractor will conduct all interventions.
  • The RCT has the potential to provide a non-pharmacological treatment option for migraineurs.
  • Risk for dropouts is increased due to strict exclusion criteria and 17?months duration of the RCT.
  • A generally accepted placebo has not been established for manual therapy; thus, there is a risk for unsuccessful blinding, while the investigator who provides the interventions cannot be blinded for obvious reasons.

 

Background

 

Migraine is a common health problem with substantial health and socioeconomic costs. On the recent Global Burden of Disease study, migraine was ranked as the third most common condition.[1]

 

Image of a woman with a migraine demonstrated by lightning coming out of her head.

 

About 15% of the general population have migraine.[2, 3] Migraine is usually unilateral with pulsating and moderate/severe headache which is aggravated by routine physical activity, and is accompanied by photophobia and phonophobia, nausea and sometimes vomiting.[4] Migraine exists in two major forms, migraine without aura and migraine with aura (below). Aura is reversible neurological disturbances of the vision, sensory and/or speech function, occurring prior to the headache. However, intraindividual variations from attack to attack are common.[5, 6] The origin of migraine is debated. The painful impulses may originate from the trigeminal nerve, central and/or peripheral mechanisms.[7, 8] Extracranial pain sensitive structures include the skin, muscles, arteries, periosteum and joints. The skin is sensitive to all usual forms of pain stimuli, while temporal and neck muscles may especially be sources for pain and tenderness in migraine.[9�11] Similarly, the frontal supraorbital, superficial temporal, posterior and occipital arteries are sensitive to pain.[9, 12]

 

Notes

 

The International Classification of Headache Disorders-II Diagnostic Criteria for Migraine

 

Migraine without Aura

  • A. At least five attacks fulfilling criteria B�D
  • B. Headache attacks lasting 4�72?h (untreated or unsuccessfully treated)
  • C. Headache has at least two of the following characteristics:
  • 1. Unilateral location
  • 2. Pulsating quality
  • 3. Moderate or severe pain intensity
  • 4. Aggravated by or causing avoidance of routine physical activity
  • D. During headache at least one of the following:
  • 1. Nausea and/or vomiting
  • 2. Photophobia and phonophobia
  • E. Not attributed to another disorder
  • Migraine with aura
  • A. At least two attacks fulfilling criteria B�D
  • B. Aura consisting of at least one of the following, but no motor weakness:
  • 1. Fully reversible visual symptoms including positive features (ie, flickering lights, spots or lines) and/or negative features (ie, loss of vision). Moderate or severe pain intensity
  • 2. Fully reversible sensory symptoms including positive features (ie, pins and needles) and/or negative features (ie, numbness)
  • 3. Fully reversible dysphasic speech disturbance
  • C. At least two of the following:
  • 1. Homonymous visual symptoms and/or unilateral sensory symptoms
  • 2. At least one aura symptom develops gradually over ?5?min and/or different aura symptoms occur in succession over ?5?min
  • 3. Each symptom lasts ?5 and ?60?min
  • D. Headache fulfilling criteria B-D for 1.1 Migraine without aura begins during the aura or follows the aura within 60?min
  • E. Not attributed to another disorder

 

Pharmacological management is the first treatment option for migraineurs. However, some patients do not tolerate acute and/or prophylactic medicine due to side effects or contraindications due to comorbidity of other diseases or due to a wish to avoid medication for other reasons. The risk of medication overuse due to frequent migraine attacks represents a major health hazard with direct and indirect cost concerns. The prevalence of medication overuse headache (MOH) is 1�2% in the general population,[13�15] that is, about half the population suffering chronic headache (15 headache days or more per month) have MOH.[16] Migraine causes loss of 270 workdays per year per 1000 persons from the general population.[17] This corresponds to about 3700 work years lost per year in Norway due to migraine. The economic cost per migraineur was estimated to be $655 in USA and �579 in Europe per year.[18, 19] Owing to the high prevalence of migraine, the total cost per year was estimated to be $14.4 billion in the USA and �27 billion in the EU countries, Iceland, Norway and Switzerland at that time. Migraine costs more than neurological disorders such as dementia, multiple sclerosis, Parkinson’s disease and stroke.[20] Thus, non-pharmacological treatment options are warranted.

 

The Diversified technique and the Gonstead method are the two most commonly used chiropractic manipulative treatment modalities in the profession, used by 91% and 59%, respectively,[21, 22] along with other manual and non-manual interventions, that is, soft tissue techniques, spinal and peripheral mobilisation, rehabilitation, postural corrections and exercises as well as general nutrition and dietetic advice.

 

A few spinal manipulative therapy (SMT) randomised controlled trials (RCTs) using the Diversified technique have been conducted for migraine, suggesting an effect on migraine frequency, migraine duration, migraine intensity and medicine consumption.[23�26] However, common for previous RCTs are the methodological shortcomings such as inaccurate headache diagnosis, that is, questionnaire diagnoses used are imprecise,[27] inadequate or no randomisation procedure, lack of placebo group, and primary and secondary end points not prespecified.[28�31] In addition, previous RCTs did not consequently adhere to the recommended clinical guidelines from the International Headache Society (IHS).[32, 33] At present, no RCTs have applied the Gonstead chiropractic SMT (CSMT) method. Thus, considering the methodological shortcomings in previous RCTs, a clinical placebo-controlled RCT with improved methodological quality remains to be conducted for migraine.

 

The SMT mechanism of action on migraine is unknown. It is argued that migraine might originate from a complexity of nociceptive afferent responses involving the upper cervical spine (C1, C2 and C3), leading to a hypersensitivity state of the trigeminal pathway conveying sensory information for the face and much of the head.[34, 35] Research has thus suggested that SMT may stimulate neural inhibitory systems at different spinal cord levels, and might activate various central descending inhibitory pathways.[36�40] However, although the proposed physiological mechanisms are not fully understood, there are most likely additional unexplored mechanisms which could explain the effect SMT has on mechanical pain sensitisation.

 

Double image of a woman with a migraine and a diagram showcasing the human brain during a migraine.

 

The objective of this study is to assess the efficacy of CSMT versus placebo (sham manipulation) and controls (continue usual pharmacological management without receiving manual intervention) for migraineurs in an RCT.

 

Method and Design

 

This is a single-blinded placebo-controlled RCT with three parallel groups (CSMT, placebo and control). Our primary hypothesis is that CSMT gives at least 25% reduction in the average number of migraine days per month (30?days/month) as compared to placebo and control from baseline to the end of intervention, and we expect the same reduction to be maintained at 3, 6 and 12?months follow-up. If the CSMT treatment is effective, it will be offered to participants who received placebo or control after study completion, that is, after 12?months follow-up. The study will adhere to the recommended clinical trial guidelines from the IHS,32 33 and the methodological CONSORT and SPIRIT guidelines.[41, 42]

 

Patient Population

 

Participants will be recruited in the period January to September 2013 through the Akershus University Hospital, through general practitioners and media advertisement, that is, posters with general information will be put up at general practitioners� offices along with oral information in the Akershus and Oslo counties, Norway. Participants will receive posted information about the project followed by a short telephone interview. Those recruited from the general practitioners� offices will have to contact the clinical investigator whose contact details have been provided on the posters in order to obtain extensive information about the study.

 

Eligible participants are between 18 and 70?years of age and have at least one migraine attack per month. Participants are diagnosed according to the diagnostic criteria of the International Classification of Headache Disorders (ICHD-II) by a neurologist at the Akershus University Hospital.[43] They are only allowed to have co-occurrence of tension-type headache and not other primary headaches.

 

Exclusion criteria are contraindication to SMT, spinal radiculopathy, pregnancy, depression and CSMT within the previous 12?months. Participants whom during the RCT receive any manual interventions by physiotherapists, chiropractors, osteopaths or other health professionals to treat musculoskeletal pain and disability, including massage therapy, joint mobilisation and manipulation,[44] changed their prophylactic headache medicine or pregnancy will be withdrawn from the study at that time and be regarded as dropouts. They are allowed to continue and change their usual acute migraine medication throughout the trial.

 

In response to initial contact, participants fulfilling the inclusion criteria will be invited to further assessment by the chiropractic investigator. The assessment includes an interview and a physical examination with special emphasis on the whole spinal column. Oral and written information about the project will be provided in advance and oral and written consent will be obtained from all accepted participants during the interview and by the clinical investigator. In accordance with good clinical practice, all patients will be informed about the harms and benefits as well as possible adverse reactions of the intervention primarily including local tenderness and tiredness on the treatment day. No serious adverse events have been reported for the chiropractic Gonstead method.[45, 46] Participants randomised into active or placebo interventions will undergo a full spine radiographic examination and be scheduled for 12 intervention sessions. The control group will not be exposed to this assessment.

 

Clinical RCT

 

The clinical RCT consists of a 1?month run-in and 3?months intervention. Time profile will be assessed from baseline to the end of follow-up for all end points (Figure 1).

 

Figure 1 Study Flow Chart

Figure 1: Study flow chart. CSMT, chiropractic spinal manipulative therapy; Placebo, sham manipulation; Control, continue usual pharmacological management without receiving manual intervention.

 

Run-In

 

The participants will fill in a validated diagnostic paper headache diary 1?month prior to intervention which will be used as baseline data for all participants.[47, 48] The validated diary includes questions directly related to the primary and secondary end points. X-rays will be taken in standing position in the anterioposterior and lateral planes of the entire spine. The X-rays will be assessed by the chiropractic investigator.

 

Randomisation

 

Prepared sealed lots with the three interventions, that is, active treatment, placebo and the control group, will be subdivided into four subgroups by age and gender, that is, 18�39 and 40�70?years of age and men and women, respectively. Participants will be equally allocated to the three groups by allowing the participant to draw one lot only. The block randomisation will be administrated by an external trained party with no involvement from the clinical investigator.

 

Intervention

 

Active treatment consists of CSMT using the Gonstead method,[21] that is, a specific contact, high-velocity, low-amplitude, short-lever spinal with no postadjustment recoil directed to spinal biomechanical dysfunction (full spine approach) as diagnosed by standard chiropractic tests.

 

The placebo intervention consists of sham manipulation, that is, a broad non-specific contact, low-velocity, low-amplitude sham push manoeuvre in a non-intentional and non-therapeutic directional line. All the non-therapeutic contacts will be performed outside the spinal column with adequate joint slack and without soft tissue pretension so that no joint cavitations occur. In some sessions, the participant lay either prone on a Zenith 2010 HYLO bench with the investigator standing at the participant’s right side with his left palm placed on the participant’s right lateral scapular edge with the other hand reinforcing. In other sessions, the investigator will stand at the participant’s left side and place his right palm over the participant’s left scapular edge with the left hand reinforcing, delivering a non-intentional lateral push manoeuvre. Alternatively, the participant lay in the same side posture position as the active treatment group with the bottom leg straight and the top leg flexed with the top leg’s ankle resting on the bottom leg’s knee fold, in preparation for a side posture push move, which will be delivered as a non-intentional push in the gluteal region. The sham manipulation alternatives will be equally interchanged among the placebo participants according to protocol during the 12-week treatment period to strengthen the study validity. The active and the placebo groups will receive the same structural and motion assessment prior to and after each intervention. No additional cointerventions or advice will be given to participants during the trial period. The treatment period will include 12 consultations, that is, twice per week in the first 3?weeks followed by once a week in the next 2?weeks and once every second week until 12?weeks are reached. Fifteen minutes will be allocated per consultation for each participant. All interventions will be conducted at the Akershus University Hospital and administered by an experienced chiropractor (AC).

 

Image of an older man receiving chiropractic care for migraine relief.

 

Dr Jimenez works on wrestler's neck_preview

 

The control group will continue usual care, that is, pharmacological management without receiving manual intervention by the clinical investigator. The same exclusion criteria apply for the control group during the whole study period.

 

Blinding

 

After each treatment session, the participants who receive active or placebo intervention will complete a de-blinding questionnaire administrated by an external trained independent party with no involvement from the clinical investigator, that is, providing a dichotomous �yes� or �no� answer as to whether active treatment was received. This response was followed by a second question regarding how certain they were that active treatment was received on a 0�10 numeric rating scale (NRS), where 0 represents absolutely uncertain and 10 represents absolutely certainty. The control group and the clinical investigator can for obvious reasons not be blinded.[49, 50]

 

Follow-Up

 

Follow-up analysis will be conducted on the end points measured after the end of intervention and at 3, 6 and 12?months follow-up. During this period, all participants will continue to fill in a diagnostic paper headache diary and return it on a monthly basis. In the case of unreturned diary or missing values in the diary, the participants will be contacted immediately on detection to minimise recall bias. Participants will be contacted by phone to secure compliance.

 

Primary and Secondary End Points

 

The primary and secondary end points are listed below. The end points adhere to the recommended IHS clinical trial guidelines.[32, 33] We define number of migraine days as the primary end point and expect at least a 25% reduction in average number of days from baseline to the end of intervention, with the same level of reduction being maintained at follow-up. On the basis of previous reviews on migraine, a 25% reduction is considered to be a conservative estimate.[30] A 25% reduction is also expected in secondary end points from baseline to the end of intervention, retaining at follow-up for migraine duration, migraine intensity and headache index, where the index is calculated as number of migraine days (30?days)�average migraine duration (hours per day)�average intensity (0�10 NRS). A 50% reduction in medication consumption from baseline to the end of intervention and to follow-up is expected.

 

Notes

 

Primary and Secondary End Points

 

Primary End Points

  • 1. Number of migraine days in active treatment versus placebo group.
  • 2. Number of migraine days in active treatment versus control group.

Secondary End Points

  • 3. Migraine duration in hours in active treatment versus placebo group.
  • 4. Migraine duration in hours in active treatment versus control group.
  • 5. Self-reported VAS in active treatment versus placebo group.
  • 6. Self-reported VAS in active treatment versus control group.
  • 7. Headache index (frequency x duration x intensity) in active treatment versus placebo group.
  • 8. Headache index in active treatment versus control group.
  • 9. Headache medication dosage in active treatment versus placebo group.
  • 10. Headache medication dosage in active treatment versus control group.

 

*The data analysis is based on the run-in period versus end of intervention. Point 11�40 will be duplicate of point 1�10 above at 3, 6 and 12?months follow-up, respectively.

 

Data Processing

 

A flow chart of the participants is shown in Figure 2. Baseline demographic and clinical characteristics will be tabulated as means and SDs for continuous variables and proportions and percentages for categorical variables. Each of three groups will be described separately. Primary and secondary end points will be presented by suitable descriptive statistics in each group and for each time point. Normality of end points will be assessed graphically and transformation will be considered if necessary.

 

Figure 2 Expected Participant's Flow Diagram

Figure 2: Expected participant’s flow diagram. CSMT, chiropractic spinal manipulative therapy; Placebo, sham manipulation; Control, continue usual pharmacological management without receiving manual intervention.

 

Change in primary and secondary end points from baseline to the end of intervention and to follow-up will be compared between the active and placebo groups and the active and control groups. The null hypothesis states that there is no significant difference between the groups in average change, while the alternative hypothesis states that a difference of at least 25% exists.

 

Owing to the follow-up period, repeated recordings of primary and secondary end points will be available, and analyses of trend in primary and secondary end points will be of main interest. Intra-individual correlations (cluster effect) are likely to be present in data with repeated measurements. Cluster effect will thus be assessed by calculating intraclass correlation coefficient quantifying the proportion of total variation attributable to the intraindividual variations. The trend in end points will be assessed by a linear regression model for longitudinal data (linear mixed model) to correctly account for the possible cluster effect. The linear mixed model handles unbalanced data, enabling all available information from randomised patients to be included, as well as from dropouts. Regression models with fixed effects for time component and group allocation as well as the interaction between the two will be estimated. The interaction will quantify possible differences between groups regarding time trend in the end points and serve as an omnibus test. Random effects for patients will be included to adjust the estimates for intraindividual correlations. Random slopes will be considered. The linear mixed models will be estimated by the SAS PROC MIXED procedure. The two pairwise comparisons will be performed by deriving individual time point contrasts within each group with the corresponding p values and 95% CIs.

 

Both per-protocol and intention-to-treat analyses will be conducted if relevant. All analyses will be performed by a statistician, blinded for group allocation and participants. All adverse effects will also be registered and presented. Participants who experience any sort of adverse effects during the trial period will be entitled to call the clinical investigator on the project cell phone. The data will be analysed with SPSS V.22 and SAS V.9.3. Owing to two group comparisons in the primary end point, p values below 0.025 will be considered statistically significant. For all secondary end points and analyses, a significance level of 0.05 will be used. Missing values might appear in incomplete interview questionnaires, incomplete headache diaries, missed intervention sessions and/or due to dropouts. The pattern of missingness will be assessed and missing values handled adequately.

 

Power Calculation

 

Sample size calculations are based on the results in a recently published group comparison study on topiramate.[51] We hypothesise that the average difference in reduction of number of days with migraine per month between the active and the placebo groups is 2.5?days. The same difference is assumed between the active and control groups. SD for reduction in each group is assumed to be equal to 2.5. Under the assumption of, on average, 10 migraine days per month at baseline in each group and no change in the placebo or control group during the study, 2.5?days reduction corresponds to a reduction by 25%. Since primary analysis includes two group comparisons, we set a significance level at 0.025. A sample size of 20 patients is required in each group to detect a statistically significant average difference in reduction of 25% with 80% power. To allow for dropouts, the investigators plan to recruit 120 participants.

 

Dr Jimenez White Coat

Dr. Alex Jimenez’s Insight

“I’ve been recommended to seek chiropractic care for my migraine-type headaches. Is chiropractic spinal manipulative therapy effective for migraine?”�Many different types of treatment options can be utilized to effectively treat migraine, however, chiropractic care is one of the most popular treatment approaches for naturally treating migraine. Chiropractic spinal manipulative therapy�is the traditional high-velocity low-amplitude (HVLA) thrust. Also known as spinal manipulation, a chiropractor performs this chiropractic technique by applying a controlled sudden force to a joint while the body is positioned in a specific way. According to the following article, chiropractic spinal manipulative therapy can effectively help treat migraine.

 

Discussion

 

Methodological Considerations

 

Current SMT RCTs on migraine suggest treatment efficacy regarding migraine frequency, duration and intensity. However, a firm conclusion requires clinical single-blinded placebo-controlled RCTs with few methodological shortcomings.[30] Such studies should adhere to the recommended IHS clinical trial guidelines with migraine frequency as the primary end point and migraine duration, migraine intensity, headache index and medication consumption as secondary end points.[32, 33] The headache index, as well as a combination of frequency, duration and intensity, gives an indication of the total level of suffering. Despite the lack of consensus, the headache index has been recommended as an accepted standard secondary end point.[33, 52, 53] The primary and secondary end points will be collected prospectively in a validated diagnostic headache diary for all participants in order to minimise recall bias.[47, 48] To the best of our knowledge, this is the first prospective manual therapy in a three-armed single-blinded placebo-controlled RCT to be conducted for migraine. The study design adheres to the recommendations for pharmacological RCTs as far as possible. RCTs that include a placebo group and a control group are advantageous to pragmatic RCTs that compare two active treatment arms. RCTs also provide the best approach for producing safety as well as efficacy data.

 

Image of a woman with a migraine holding her head.

 

Unsuccessful blinding is a possible risk to the RCT. Blinding is often difficult as there is no single validated standardised chiropractic sham intervention which can be used as a control group for this date. It is, however, necessary to include a placebo group in order to produce a true net effect of the active intervention. Consensus about an appropriate placebo for a clinical trial of SMT among experts representing clinicians and academics has, however, not been reached.[54] No previous studies have, to the best of our knowledge, validated a successful blinding of a CSMT clinical trial with multiple treatment sessions. We intend to minimise this risk by following the proposed protocol for the placebo group.

 

The placebo response is furthermore high in pharmacological and assumed similarly high for non-pharmacological clinical studies; however, it might even be higher in manual therapy RCTs were attention and physical contact is involved.[55] Similarly, a natural concern with regard to attention bias will be involved for the control group as it is not being seen by anyone or not seen as much by the clinical investigator as the other two groups.

 

There are always risks for dropouts due to various reasons. Since the trial duration is 17?months with a 12?month follow-up period, the risk for loss to follow-up is thus enhanced. Co-occurrence of other manual intervention during the trial period is another possible risk, as those who receive manipulation or other manual physical treatments elsewhere during the trial period will be withdrawn from the study and regarded as dropouts at the time of violation.

 

The external validity of the RCT might be a weakness as there is only one investigator. However, we found that advantageous to multiple investigators, in order to provide similar information to participants in all three groups and manual intervention in the CSMT and the placebo groups. Thus, we intend to eliminate inter-investigator variability which might be present if there are two or more investigators. Although the Gonstead method is the second most commonly used technique among chiropractors, we do not see an issue of concern when it comes to generalisability and external validity. Furthermore, the block randomisation procedure will provide a homogeneous sample across the three groups.

 

The internal validity is, however, strong by having one treating clinician. It reduces the risk of potential selection, information and experimental biases. Furthermore, the diagnosis of all participants is performed by experienced neurologists and not by questionnaires. A direct interview has higher sensitivity and specificity as compared to a questionnaire.[27] Individual motivational factors which can influence a participant’s perception and personal preferences when treating are both reduced by having one investigator. In addition, the internal validity is further strengthened by a concealed validated randomisation procedure. Since age and genders may play a role in migraine, block randomisation was found necessary to balance arms by age and gender in order to reduce possible age-related and/or gender-related bias.

 

Image of X-rays demonstrating loss of cervical lordosis as a possible cause for migraine.

X-rays demonstrating loss of cervical lordosis as a possible cause for migraine.

 

Conducting X-rays prior to the active and placebo interventions was found to be applicable in order to visualise posture, joint and disc integrity.[56, 57] Since the total X-ray radiation dose varies from 0.2�0.8?mSv, the radiation exposure was considered low.[58, 59] X-ray assessments were also found to be necessary in order to determine if full spine X-rays are useful in future studies or not.

 

Since we are unaware of the mechanisms of possible efficacy, and both spinal cord and central descending inhibitory pathways have been postulated, we see no reasons to exclude a full spine treatment approach for the intervention group. It has furthermore been postulated that pain in different spinal regions should not be regarded as separate disorders but rather as a single entity.[60] Similarly, including a full spine approach limits the differentiations between the CSMT and the placebo groups. Thus, it might strengthen the likelihood of successful blinding in the placebo group being achieved. In addition, all the placebo contacts will be performed outside the spinal column, thus minimising a possible spinal cord afferent input.

 

Innovative and Scientific Value

 

This RCT will highlight and validate the Gonstead CSMT for migraineurs, which has not previously been studied. If CSMT proves to be effective, it will provide a non-pharmacological treatment option. This is especially important as some migraineurs do not have efficacy of prescript acute and/or prophylactic medications, while others have non-tolerable side effects or comorbidity of other diseases that contradict medication while others wish to avoid medication for various reasons. Thus, if CSMT works, it can really have an impact on migraine treatment. The study also bridges cooperation between chiropractors and physicians, which is important in order to make healthcare more efficient. Finally, our method might be applied in future chiropractic and other manual therapy RCTs on headache.

 

Ethics and Dissemination

 

Ethics

 

The study has been approved by the Norwegian Regional Committee for Medical Research Ethics (REK) (2010/1639/REK) and the Norwegian Social Science Data Services (11�77). The declaration of Helsinki is otherwise followed. All data will be anonymised while participants must give oral and written informed consent. Insurance is provided through �The Norwegian System of Compensation to Patients� (NPE), which is an independent national body set up to process compensation claims from patients who have suffered an injury as a result of treatment under the Norwegian health service. A stopping rule was defined for withdrawing participants from this study in accordance with recommendations in the CONSORT extension for Better Reporting of Harms.[61] If a participant reports to their chiropractor or research staff a severe adverse event, he or she will be withdrawn from the study and referred to their general practitioner or hospital emergency department depending on the nature of the event. The final data set will be available to the clinical investigator (AC), the independent and blinded statistician (JSB) and Study Director (MBR). Data will be stored in a locked cabinet at the Research Centre, Akershus University Hospital, Norway, for 5?years.

 

Dissemination

 

This project is due for completion 3?years after the start. Results will be published in peer-reviewed international scientific journals in accordance with the CONSORT 2010 Statement. Positive, negative, as well as inconclusive results will be published. In addition, a written lay summary of the results will be available to study participants on request. All authors should qualify for authorship according to the International Committee of Medical Journal Editors, 1997. Each author should have participated sufficiently in the work to take public responsibility for the content. The final decision on the order of authorship will be decided when the project has been finalised. The results from the study may, moreover, be presented as posters or oral presentations at national and/or international conferences.

 

Acknowledgments

 

Akershus University Hospital kindly provided research facilities. Chiropractor Clinic1, Oslo, Norway, performed X-ray assessments.

 

Footnotes

 

Contributors: AC and PJT had the original idea for the study. AC and MBR obtained funding. MBR planned the overall design. AC prepared the initial draft and PJT commented on the final version of the research protocol. JSB performed all the statistical analyses. AC, JSB, PJT and MBR were involved in the interpretation and assisted in the revision and preparation of the manuscript. All authors have read and approved the final manuscript.

 

Funding: The study has received funding from Extrastiftelsen (grant number: 2829002), the Norwegian Chiropractic Association (grant number: 2829001), Akershus University Hospital (grant number: N/A) and University of Oslo in Norway (grant number: N/A).

 

Competing interests: None declared.

 

Patient consent: Obtained.

 

Ethics approval: The Norwegian Regional Committee for Medical Research Ethics approved the project (ID of the approval: 2010/1639/REK).

 

Provenance and peer review: Not commissioned; externally peer reviewed.

 

A Randomized Controlled Trial of Chiropractic Spinal Manipulative Therapy for Migraine

 

Abstract

 

Objective: To assess the efficacy of chiropractic spinal manipulative therapy (SMT) in the treatment of migraine.

 

Design: A randomized controlled trial of 6 months’ duration. The trial consisted of 3 stages: 2 months of data collection (before treatment), 2 months of treatment, and a further 2 months of data collection (after treatment). Comparison of outcomes to the initial baseline factors was made at the end of the 6 months for both an SMT group and a control group.

 

Setting: Chiropractic Research Center of Macquarie University.

 

Participants: One hundred twenty-seven volunteers between the ages of 10 and 70 years were recruited through media advertising. The diagnosis of migraine was made on the basis of the International Headache Society standard, with a minimum of at least one migraine per month.

 

Interventions: Two months of chiropractic SMT (diversified technique) at vertebral fixations determined by the practitioner (maximum of 16 treatments).

 

Main Outcome Measures: Participants completed standard headache diaries during the entire trial noting the frequency, intensity (visual analogue score), duration, disability, associated symptoms, and use of medication for each migraine episode.

 

Results: The average response of the treatment group (n = 83) showed statistically significant improvement in migraine frequency (P < .005), duration (P < .01), disability (P < .05), and medication use (P< .001) when compared with the control group (n = 40). Four persons failed to complete the trial because of a variety of causes, including change in residence, a motor vehicle accident, and increased migraine frequency. Expressed in other terms, 22% of participants reported more than a 90% reduction of migraines as a consequence of the 2 months of SMT. Approximately 50% more participants reported significant improvement in the morbidity of each episode.

 

Conclusion: The results of this study support previous results showing that some people report significant improvement in migraines after chiropractic SMT. A high percentage (>80%) of participants reported stress as a major factor for their migraines. It appears probable that chiropractic care has an effect on the physical conditions related to stress and that in these people the effects of the migraine are reduced.

 

In conclusion, chiropractic spinal manipulative therapy can be used effectively to help treat migraine, according to the research study. Furthermore, chiropractic care improved the individual’s overall health and wellness. The well-being of the human body as a whole is believed to be one of the biggest factors as to why chiropractic care is effective for migraine. Information referenced from the National Center for Biotechnology Information (NCBI). The scope of our information is limited to chiropractic as well as to spinal injuries and conditions. To discuss the subject matter, please feel free to ask Dr. Jimenez or contact us at 915-850-0900 .

 

Curated by Dr. Alex Jimenez

 

Green-Call-Now-Button-24H-150x150-2-3.png

 

Additional Topics: Neck Pain

 

Neck pain is a common complaint which can result due to a variety of injuries and/or conditions. According to statistics, automobile accident injuries and whiplash injuries are some of the most prevalent causes for neck pain among the general population. During an auto accident, the sudden impact from the incident can cause the head and neck to jolt abruptly back-and-forth in any direction, damaging the complex structures surrounding the cervical spine. Trauma to the tendons and ligaments, as well as that of other tissues in the neck, can cause neck pain and radiating symptoms throughout the human body.

 

blog picture of cartoon paperboy big news

 

IMPORTANT TOPIC: EXTRA EXTRA: A Healthier You!

 

Blank
References
1. Vos T, Flaxman AD, Naghavi M et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990�2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163�96. doi:10.1016/S0140-6736(12)61729-2 [PubMed]
2. Russell MB, Kristiansen HA, Saltyte-Benth J et al. A cross-sectional population-based survey of migraine and headache in 21,177 Norwegians: the Akershus sleep apnea project. J Headache Pain 2008;9:339�47. doi:10.1007/s10194-008-0077-z [PMC free article] [PubMed]
3. Steiner TJ, Stovner LJ, Katsarava Z et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 2014;15:31 doi:10.1186/1129-2377-15-31 [PMC free article] [PubMed]
4. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629�808. doi:10.1177/0333102413485658 [PubMed]
5. Russell MB, Iversen HK, Olesen J. Improved description of the migraine aura by a diagnostic aura diary. Cephalalgia 1994;14:107�17. doi:10.1046/j.1468-2982.1994.1402107.x [PubMed]
6. Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain 1996;119(Pt 2):355�61. doi:10.1093/brain/119.2.355 [PubMed]
7. Olesen J, Burstein R, Ashina M et al. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 2009;8:679�90. doi:10.1016/S1474-4422(09)70090-0 [PubMed]
8. Amin FM, Asghar MS, Hougaard A et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol 2013;12:454�61. doi:10.1016/S1474-4422(13)70067-X [PubMed]
9. Wolff HGF. Headache and other head pain. 2nd edn Oxford: Oxford University Press, 1963.
10. Jensen K. Extracranial blood flow, pain and tenderness in migraine. Clinical and experimental studies. Acta Neurol Scand Suppl 1993;147:1�8. doi:10.1111/j.1748-1716.1993.tb09466.x [PubMed]
11. Svensson P, Ashina M. Human studies of experimental pain from muscles. In: Olesen J, Tfelt-Hansen P, Welch KMA et al., eds Headache. 3rd edn Lippincott Williams & Wilkins, 2006:627�35.
12. Ray BS, Wolff HG. Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch Surg 1940;41:813�56. doi:10.1001/archsurg.1940.01210040002001
13. Grande RB, Aaseth K, Gulbrandsen P et al. Prevalence of primary chronic headache in a population-based sample of 30- to 44-year-old persons. The Akershus study of chronic headache. Neuroepidemiology 2008;30:76�83. doi:10.1159/000116244 [PubMed]
14. Aaseth K, Grande RB, Kvaerner KJ et al. Prevalence of secondary chronic headaches in a population-based sample of 30�44-year-old persons. The Akershus study of chronic headache. Cephalalgia 2008;28:705�13. doi:10.1111/j.1468-2982.2008.01577.x [PubMed]
15. Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol 2008;7:354�61. doi:10.1016/S1474-4422(08)70062-0 [PubMed]
16. Lundqvist C, Grande RB, Aaseth K et al. Dependence scores predict prognosis of medication overuse headache: a prospective cohort from the Akershus study of chronic headache. Pain 2012;153:682�6. doi:10.1016/j.pain.2011.12.008 [PubMed]
17. Rasmussen BK, Jensen R, Olesen J. Impact of headache on sickness absence and utilisation of medical services: a Danish population study. J Epidemiol Community Health 1992;46:443�6. doi:10.1136/jech.46.4.443 [PMC free article] [PubMed]
18. Hu XH, Markson LE, Lipton RB et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999;159:813�18. doi:10.1001/archinte.159.8.813 [PubMed]
19. Berg J, Stovner LJ. Cost of migraine and other headaches in Europe. Eur J Neurol 2005;12(Suppl 1):59�62. doi:10.1111/j.1468-1331.2005.01192.x [PubMed]
20. Andlin-Sobocki P, Jonsson B, Wittchen HU et al. Cost of disorders of the brain in Europe. Eur J Neurol 2005;12(Suppl 1):1�27. doi:10.1111/j.1468-1331.2005.01202.x [PubMed]
21. Cooperstein R. Gonstead Chiropractic Technique (GCT). J Chiropr Med 2003;2:16�24. doi:10.1016/S0899-3467(07)60069-X [PMC free article] [PubMed]
22. Cooperstein R, Gleberson BJ. Technique systems in chiropractic. 1st edn New York: Churchill Livingston, 2004.
23. Parker GB, Tupling H, Pryor DS. A controlled trial of cervical manipulation of migraine. Aust NZ J Med 1978;8:589�93. doi:10.1111/j.1445-5994.1978.tb04845.x [PubMed]
24. Parker GB, Pryor DS, Tupling H. Why does migraine improve during a clinical trial? Further results from a trial of cervical manipulation for migraine. Aust NZ J Med 1980;10:192�8. doi:10.1111/j.1445-5994.1980.tb03712.x [PubMed]
25. Nelson CF, Bronfort G, Evans R et al. The efficacy of spinal manipulation, amitriptyline and the combination of both therapies for the prophylaxis of migraine headache. J Manipulative Physiol Ther 1998;21:511�19. [PubMed]
26. Tuchin PJ, Pollard H, Bonello R. A randomized controlled trial of chiropractic spinal manipulative therapy for migraine. J Manipulative Physiol Ther 2000;23:91�5. doi:10.1016/S0161-4754(00)90073-3 [PubMed]
27. Rasmussen BK, Jensen R, Olesen J. Questionnaire versus clinical interview in the diagnosis of headache. Headache 1991;31:290�5. doi:10.1111/j.1526-4610.1991.hed3105290.x [PubMed]
28. Vernon HT. The effectiveness of chiropractic manipulation in the treatment of headache: an exploration in the literature. J Manipulative Physiol Ther 1995;18:611�17. [PubMed]
29. Fernandez-de-las-Penas C, Alonso-Blanco C, San-Roman J et al. Methodological quality of randomized controlled trials of spinal manipulation and mobilization in tension-type headache, migraine, and cervicogenic headache. J Orthop Sports Phys Ther 2006;36:160�9. doi:10.2519/jospt.2006.36.3.160 [PubMed]
30. Chaibi A, Tuchin PJ, Russell MB. Manual therapies for migraine: a systematic review. J Headache Pain 2011;12:127�33. doi:10.1007/s10194-011-0296-6 [PMC free article] [PubMed]
31. Chaibi A, Russell MB. Manual therapies for primary chronic headaches: a systematic review of randomized controlled trials. J Headache Pain 2014;15:67 doi:10.1186/1129-2377-15-67 [PMC free article] [PubMed]
32. Tfelt-Hansen P, Block G, Dahlof C et al. International Headache Society Clinical Trial Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20:765�86. doi:10.1046/j.1468-2982.2000.00117.x [PubMed]
33. Silberstein S, Tfelt-Hansen P, Dodick DW et al. , Task Force of the International Headache Society Clinical Trial Subcommittee . Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008;28:484�95. doi:10.1111/j.1468-2982.2008.01555.x [PubMed]
34. Kerr FW. Central relationships of trigeminal and cervical primary afferents in the spinal cord and medulla. Brain Res 1972;43:561�72. doi:10.1016/0006-8993(72)90408-8 [PubMed]
35. Bogduk N. The neck and headaches. Neurol Clin 2004;22:151�71, vii doi:10.1016/S0733-8619(03)00100-2 [PubMed]
36. McLain RF, Pickar JG. Mechanoreceptor endings in human thoracic and lumbar facet joints. Spine (Phila Pa 1976) 1998;23:168�73. doi:10.1097/00007632-199801150-00004 [PubMed]
37. Vernon H. Qualitative review of studies of manipulation-induced hypoalgesia. J Manipulative Physiol Ther 2000;23:134�8. doi:10.1016/S0161-4754(00)90084-8 [PubMed]
38. Vicenzino B, Paungmali A, Buratowski S et al. Specific manipulative therapy treatment for chronic lateral epicondylalgia produces uniquely characteristic hypoalgesia. Man Ther 2001;6:205�12. doi:10.1054/math.2001.0411 [PubMed]
39. Boal RW, Gillette RG. Central neuronal plasticity, low back pain and spinal manipulative therapy. J Manipulative Physiol Ther 2004;27:314�26. doi:10.1016/j.jmpt.2004.04.005 [PubMed]
40. De Camargo VM, Alburquerque-Sendin F, Berzin F et al. Immediate effects on electromyographic activity and pressure pain thresholds after a cervical manipulation in mechanical neck pain: a randomized controlled trial. J Manipulative Physiol Ther 2011;34:211�20. doi:10.1016/j.jmpt.2011.02.002 [PubMed]
41. Moher D, Hopewell S, Schulz KF et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869 doi:10.1136/bmj.c869 [PMC free article] [PubMed]
42. Hoffmann TC, Glasziou PP, Boutron I et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014;348:g1687 doi:10.1136/bmj.g1687 [PubMed]
43. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(Suppl 1):9�10. doi:10.1111/j.1468-2982.2003.00824.x [PubMed]
44. French HP, Brennan A, White B et al. Manual therapy for osteoarthritis of the hip or knee – a systematic review. Man Ther 2011;16:109�17. doi:10.1016/j.math.2010.10.011 [PubMed]
45. Cassidy JD, Boyle E, Cote P et al. Risk of vertebrobasilar stroke and chiropractic care: results of a population-based case-control and case-crossover study. Spine (Phila Pa 1976) 2008;33(4Suppl):S176�S83. doi:10.1097/BRS.0b013e3181644600 [PubMed]
46. Tuchin P. A replication of the study �Adverse effects of spinal manipulation: a systematic review�. Chiropr Man Therap 2012;20:30 doi:10.1186/2045-709X-20-30 [PMC free article] [PubMed]
47. Russell MB, Rasmussen BK, Brennum J et al. Presentation of a new instrument: the diagnostic headache diary. Cephalalgia 1992;12:369�74. doi:10.1111/j.1468-2982.1992.00369.x [PubMed]
48. Lundqvist C, Benth JS, Grande RB et al. A vertical VAS is a valid instrument for monitoring headache pain intensity. Cephalalgia 2009;29:1034�41. doi:10.1111/j.1468-2982.2008.01833.x [PubMed]
49. Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Control Clin Trials 2004;25:143�56. doi:10.1016/j.cct.2003.10.016 [PubMed]
50. Johnson C. Measuring Pain. Visual Analog Scale Versus Numeric Pain Scale: What is the Difference? J Chiropr Med 2005;4:43�4. doi:10.1016/S0899-3467(07)60112-8 [PMC free article] [PubMed]
51. Silberstein SD, Neto W, Schmitt J et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490�5. doi:10.1001/archneur.61.4.490 [PubMed]
52. Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry 1996;61:285�90. doi:10.1136/jnnp.61.3.285 [PMC free article] [PubMed]
53. Hagen K, Albretsen C, Vilming ST et al. Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia 2009;29:221�32. doi:10.1111/j.1468-2982.2008.01711.x [PubMed]
54. Hancock MJ, Maher CG, Latimer J et al. Selecting an appropriate placebo for a trial of spinal manipulative therapy. Aust J Physiother 2006;52:135�8. doi:10.1016/S0004-9514(06)70049-6 [PubMed]
55. Meissner K, Fassler M, Rucker G et al. Differential Effectiveness of Placebo Treatments: A Systematic Review of Migraine Prophylaxis. JAMA Inter Med 2013;173:1941�51. doi:10.1001/jamainternmed.2013.10391 [PubMed]
56. Taylor JA. Full-spine radiography: a review. J Manipulative Physiol Ther 1993;16:460�74. [PubMed]
57. International Chiropractic Assocoation Practicing Chiropractors� Committee on Radiology Protocols (PCCRP) for biomechanical assessment of spinal subluxation in chiropractic clinical practice. Secondary International Chiropractic Assocoation Practicing Chiropractors� Committee on Radiology Protocols (PCCRP) for biomechanical assessment of spinal subluxation in chiropractic clinical practice 2009. www.pccrp.org/
58. Cracknell DM, Bull PW. Organ dosimetry in spinal radiography: a comparison of 3-region sectional and full-spine techniques. Chiropr J Austr 2006;36:33�9.
59. Borretzen I, Lysdahl KB, Olerud HM. Diagnostic radiology in Norway trends in examination frequency and collective effective dose. Radiat Prot Dosimetry 2007;124:339�47. doi:10.1093/rpd/ncm204 [PubMed]
60. Leboeuf-Yde C, Fejer R, Nielsen J et al. Pain in the three spinal regions: the same disorder? Data from a population-based sample of 34,902 Danish adults. Chiropr Man Ther 2012;20:11 doi:10.1186/2045-709X-20-11 [PMC free article] [PubMed]
61. Ioannidis JP, Evans SJ, Gotzsche PC et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781�8. doi:10.7326/0003-4819-141-10-200411160-00009 [PubMed]
Close Accordion
Treatment Options for Headaches & Migraines

Treatment Options for Headaches & Migraines

The most useful rule-of-thumb for headache and migraine treatment is: Have a program. See your doctor and produce a treatment strategy together. Your program will help you identify and handle migraines or your headaches early, sparing you some discomfort.

Tension Headache Treatments

When you get a pressure-type headache, it’s usually because of a change in neck, your mind, or encounter. Other tissues, nerves, blood vessels, and the muscles are experiencing distress. Treat the change, and you will reduce your headache.

It may build up unwanted stress, in case you have already been hunched over a laptop at work. Or perhaps a new medicine was started by you, or had minor neck injuries.

Take a minute curl up to stretch, or massage head your face, and neck. Consider a nap, a shower, or utilizing pack or ice pack on your own head or neck.

Tension Headache Medications

For tension headaches, you’ve numerous over-the-counter medicine alternatives. Naproxen ibuprofen, acetaminophen, and aspirin are successful. If you suspect your headache is vascular (associated to your own blood vessels), consider a pain-reliever that includes some caffeine.

Get in touch with your doctor for more tips if your headache does not react to to your own behavioral techniques and medications. In the event the headache becomes severe or lasts for more than 10 days, see your doctor. Your headache might be a signal of another condition.

Cluster Headache Treatments

Inhaling 100% oxygen right when a cluster headache starts can help lessen the pain considerably. Your doctor can help you get a portable oxygen unit to carry in a bag or briefcase.

A mainstay migraine medication, sumatriptan, is effective for cluster headaches. Learn to inject yourself right when you sense the first signs of your cluster headache. Other cluster headache medicines that are useful are dihydroergotamine, administered via an I-V, and octreotide sent as an injection.

Migraine Headache Prevention

Over the past 2 decades, health practitioners have realized effective treatments for decreasing the frequency of migraines. Avoid migraine triggers, take preventive medicine, alter your nourishment, and improve your rest.

One of numerous migraine triggers, several are foods, by avoiding so you can reduce your migraine risk:

  • Beans, legumes, and nuts
  • Fermented and pickled foods like pickles and olives
  • Dairy and cheese that is aged
  • Avocados
  • Onions
  • Cured or ag ed meats
  • Items containing brewer’s yeast
  • Chocolate, cocoa, and carob
  • Aspartame
  • Beverages
  • Caffeine

Other frequent migraine triggers include:

  • Stress
  • Weather changes
  • Poor diet
  • Hormonal changes
  • Nicotine
  • Physical activities that are intense

As you pay focus on what triggers your migraines, you are able to learn better what to avoid�??this is just a starting listing.

Your doctor will consider other medicines that prevent migraines. He/she might prescribe:

  • The blood-pressure drugs propranolol or timolol
  • Anti-depressants such as amitriptyline or fluoxetine
  • The seizure medication valproate

While these drugs came to market to handle other conditions, they are also efficient for migraine prevention.

Migraine Treatment

Migraine remedy is a race from the clock. You can take steps to reduce the intensity of the assault when you sense the warning signs of a migraine. That is the time to lie down, relax, and simply take your drugs.

Non-steroidal anti-inflammatories (NSAIDs), aspirin, and acetaminophen relieve some migraines. However, many migraine sufferers need stronger medicines for example sumatriptan or a different medication from your triptan family. In a few extreme circumstances, you may be treated by your physician with an opioid.

Treatments such as ice packs or cold compresses on your forehead rush instant reduction. Massaging your scalp and rubbing your temples may also help reduce the intensity of the migraine.

The scope of our information is limited to chiropractic and spinal injuries and conditions. To discuss options on the subject matter, please feel free to ask Dr. Jimenez or contact us at 915-850-0900 .�Green-Call-Now-Button-24H-150x150.png

By Dr. Alex Jimenez

Additional Topics: Cervicogenic Headache and Chiropractic

Neck pain associated with whiplash-associated disorders resulting from an automobile accident are reportedly the most prevalent cause for discomfort along the cervical spine. The sheer force of an impact from a rear-end car crash or other traffic incident can cause injuries or aggravate a previously existing condition. While neck pain is commonly the result of damage to the complex structures of the neck, cervicogenic headaches may also result due to neck issues. Chiropractic care can help carefully restore the alignment of the cervical spine to relieve headaches and neck pain.

 

blog picture of cartoon paperboy big news

 

TRENDING TOPIC: EXTRA EXTRA: New PUSH 24/7�? Fitness Center